Fixation and Revision of 923 Scheduled Formulations and Retail prices of 65 formulations approved in 122 Authority meeting

2263 GI/202 4 (1) EXTRAORDINARY PART II —Section 3 —Sub-section ( ii) PUBLISHED BY AUTHORITY ( ) ( ) का. आ. 1547(अ).— , 4, 6, 10, 11, 14, 16, 17 a b No. 1478] NEW DELH I, TUES DAY , MARCH 26, 2024 /CHAITRA 6, 194 6 CG-DL-E-30032024-253444 (0.00551 % (1) (2) (3) (4) (5) (6a) (6b) 25-10-23 dSIlwy 250 fexzk - 1 dSIlwy 5.05 4663( अ) 25-10-23 ,afVªd dksfVM xksyh 75 fexzk- 1 xksyh 0.35 4663( अ) 25-10-23 dkWuosu'kuy@bQsjoslsaV @fMLijflcy@,afVªd dksfVM xksyh 150 fexzk - 1 xksyh 0.71 4663( अ) 25-10-23 vksjy fyD;wbZM 400 fexzk-@5 fefy - 1 fefy- 1.36 4663( अ) 25-10-23 vksjy fyD;wbZM 200 fexzk-@5 fefy - 1 fefy- 1.79 1577( अ) 31-03-23 xksyh 400 fexzk - 1 xksyh 7.04 1577( अ) 31-03-23 fexzk- 1 xksyh 8.13 4663( अ) 25-10-23 25-10-23 vksjy fyD;wbZM 250 fexzk-@5 fefy - (पी) 1 fefy- 1.56 4663( अ) 25-10-23 /5 मम.ली. (पी) 1 मम.ली. 1.02 1579( अ) 31-03-23 (बी) 1 वाईल 140.66 4663( अ) 25-10-23 (ए) + 31.25 ,EQksVsfjflu ch&dkWuosu'kuy batSD'ku 50 fexzk -/ वाईल 1 वाईल 227.40 1577( अ) 31-03-23 xksyh 100 fexzk - 1 xksyh 0.24 4663( अ) 25-10-23 xksyh 500 fexzk - 1 xksyh 1.48 1577( अ) 31-03-23 )बी( 1 गोली 99.83 1574( अ) 31-03-23 batSD'ku 10 fexzk - @fefy- 1 fefy- 16.98 4663( अ) 25-10-23 31-03-23 dSIlwy 250 fexzk - 1 dSIlwy 10.62 4663( अ) 25-10-23 25-10-23 वाईल 1 वाईल 4946.80 1574( अ) 31-03-23 batSD'ku 4 fexzk - @fefy- 1 fefy- 4.74 1577( अ) 31-03-23 jslfijsVkWjh lksyq'ku QkWj ;wt bu uscqykbtj 0-5 fexzk-@fefy- 1 fefy- 11.90 4663( अ) 25-10-23 jslfijsVkWjh lksyq'ku QkWj ;wt bu uscqykbtj 1 fexzk-@fefy- 1 fefy- 13.14 1577( अ) 31-03-23 batSD'ku 0 -5% ds lkFk 7-5% Xywdkst 1 fefy- 7.39 4663( अ) 25-10-23 batSD'ku 0 -50% 1 fefy- 4.42 4663( अ) 25-10-23 batSD'ku 0 -25% 1 fefy- 2.83 4663( अ) 25-10-23 25-10-23 25-10-23 batSD'ku 20 fexzk - @fefy- 1 fefy- 250.50 1577( अ) 31-03-23 yks'ku ¼vkbZih ds vuqlkj½ 1 fefy- 0.95 1577( अ) 31-03-23 dSIlwy 200 fexzk - 1 dSIlwy 14.68 4663( अ) 25-10-23 31-03-23 31-03-23 dSIlwy 60000 vkbZ;w 1 dSIlwy 30.78 4663( अ) 25-10-23 dSIlwy 1000 vkbZ;w 1 dSIlwy 4.89 4663( अ) 25-10-23 vksjy fyD;wbZM 250 fexzk-@5 fefy - (पी) 1 fefy- 0.74 1577( अ) 31-03-23 xksyh 10 fexzk - 1 xksyh 2.85 4663( अ) 25-10-23 xksyh 25 fexzk - 1 xksyh 6.22 1577( अ) 31-03-23 xksyh 75 fexzk - 1 xksyh 16.46 4663( अ) 25-10-23 yks'ku 1 % 1 fefy- 3.89 1577( अ) 31-03-23 isljh 100 fexzk - 1 isljh 10.01 1577( अ) 31-03-23 MªksIl 1 % 1 fefy- 3.37 1577( अ) 31-03-23 Øhe 1 % 1 xzke 3.00 1577( अ) 31-03-23 xksyh 400 fexzk - ¼,½ $ 80 fexzk- ¼ch½ 1 xksyh 0.90 4663( अ) 25-10-23 vksjy fyD;wbZM 200 fexzzk-¼,½ $ 40 fexzk - ¼ch½@5 fefy - 1 fefy- 0.35 4663( अ) 25-10-23 31-03-23 xksyh 50 fexzk - 1 xksyh 3.73 1577( अ) 31-03-23 xksyh 250 fexz k- 1 xksyh 46.01 1577( अ) 31-03-23 वाईल 1 वाईल 536.33 1574( अ) 31-03-23 (2 मि.ली.) 1 मि.ली. 5.09 2124( अ) 04-05-23 04-05-23 batSD'ku 4 fexzk - @fefy- ¼izfr iSd 10 fefy-½ 1 fefy- 1.57 4663( अ) 25-10-23 batSD'ku 4 f exzk- @fefy- ¼izfr iSd 20 fefy-½ 1 fefy- 1.35 4663( अ) 25-10-23 batSD'ku 4 fexzk - @fefy- ¼izfr iSd 30 fefy-½ 1 fefy- 0.90 4663( अ) 25-10-23 xksyh 2 fexzk - 1 xksyh 1.44 4663( अ) 25-10-23 lqIiksftVªh 5 fexzk - 1 lqIiksftVªh 6.19 4663( अ) 25-10-23 batSD'ku 10 fexzk - @fefy-¼10 fefy - iSd िे र्कम½ 1 fefy- 3.32 4663( अ) 25-10-23 batSD'ku 10 fexzk - @fefy-¼10 fefy - औि अधिर्क iSd½ 1 fefy- 2.10 4663( अ) 25-10-23 220 जडिोजससन vksjy fyD;wbZM 0 -05 fexzk-@ fefy- 1 fefy- 1.47 4663( अ) 25-10-23 221 जडिोजससन batSD'ku 0 -25 fexzk- @fefy- 1 fefy- 3.87 4663( अ) 25-10-23 xksyh 30 fexzk - 1 xksyh 2.68 4663( अ) 25-10-23 batSD'ku 5 fexzk - @fefy- 1 fefy- 3.50 4663( अ) 25-10-23 batSD'ku 50 fexzk - @fefy- 1 fefy- 9.03 4663( अ) 25-10-23 batSD'ku 2 fexzk - @fefy- 1 fefy- 31.75 1577( अ) 31-03-23 237 डॉससी साइजसलन xksyh 100 fexzk - 1 xksyh 1.22 1577( अ) 31-03-23 fefy- 75.65 4663( अ) 25-10-23 xksyh 200 fexzk - (पी) 1 xksyh 22.54 4663( अ) 25-10-23 batSD'ku 40 fexzk -@0-4 fefy- batSD'ku 60 fexzk -@0-6 fefy- 0-1 fefy- 111.99 4663( अ) 25-10-23 /मि.ली. 1 मि.ली. 1969.11 1574( अ) 31-03-23 batSD'ku 10 fexzk - @fefy- 1 fefy- 26.38 1577( अ) 31-03-23 xksyh 200 fexzk - 1 xksyh 1.14 1577( अ) 31-03-23 (बी) 1 गोली 3.17 1574( अ) 31-03-23 dSIlwy 200 fexzk - 1 dSIlwy 40.11 4663( अ) 25-10-23 dSIlwy 150 fexzk - 1 dSIlwy 19.22 4663( अ) 25-10-23 batSD'ku 200 fexzk -@ 100 fefy - izfr 100 fefy- वाईल 92.33 1577( अ) 31-03-23 vksjy fyD;wbZM 10 fexzk-@fefy- 1 fefy- 3.32 4663( अ) 25-10-23 मि.ली. (1.5 मि.ली.) 1 मि.ली. 2.90 2125( अ) 04-05-23 batSD'ku 40 fexzk - @fefy- ¼izfr iSd 10 fefy-½ 1 fefy- 1.51 1577( अ) 31-03-23 batSD'ku 40 fexzk - @fefy- ¼izfr iSd 20 fefy-½ 1 fefy- 1.55 4663( अ) 25-10-23 batSD'ku 40 fexzk - @fefy- ¼izfr iSd 30 fefy-½ 1 fefy- 1.23 1577( अ) 31-03-23 batSD'ku 40 fexzk - @fefy- 2 1 मि.ली. 4.85 2124( अ) 04-05-23 31-03-23 25-10-23 lcfyaxq,y xksyh 0 -5 fexzk- 1 xksyh 1.27 4663( अ) 25-10-23 batSD'ku 5 fexzk - @fefy- 1 fefy- 6.51 1577( अ) 31-03-23 xksyh 20 fexzk - 1 xksyh 5.36 4663( अ) 25-10-23 मि.ली. 1 मि.ली. 21.21 1574( अ) 31-03-23 मि.ली. 1 मि.ली. 59.96 1574( अ) 31-03-23 blesa 52 fexzk - ysoksuksxsZLVsªy 'kkfey gS 1 vkbZ;wMh 4103.53 4663( अ) 25-10-23 batSD'ku ds fy, ikmMj 2000 fexzk - 1 वाईल 643.16 4663( अ) 25-10-23 batSD'ku ds fy, ikmMj 1 वाईल 318.96 1577( अ) 31-03-23 1000 fexzk - dSIlwy 100 fexzk - 1 dSIlwy 73.48 1577( अ) 31-03-23 batSD'ku 40 vkbZ;w@fefy - 1 fefy- 16.99 4663( अ) 25-10-23 आईयू / मम.ली. 1 fefy- 203.46 4663( अ) 25-10-23 batSD'ku 300 fexzk - vk;ksfMu@fefy - 1 fefy- 16.90 4663( अ) 25-10-23 1 मि.ली. 4.94 1574( अ) 31-03-23 ykblsal ds :i esa 1 vkbZ;wMh 281.02 4663( अ) 25-10-23 /15मि.ली. 1 मि.ली. 1.23 1574( अ) 31-03-23 केयू 1 वाईल 1034.88 4663( अ) 25-10-23 10000 केयू 1 वाईल 1707.74 4663( अ) 25-10-23 मि.ली. 1 मि.ली. 23.02 4663( अ) 25-10-23 (बी) 1 गोली 2.58 4663( अ) 25-10-23 (बी) 1 गोली 1.76 1574( अ) 31-03-23 batSD'ku 1 % 1 fefy- 8.87 4663( अ) 25-10-23 batSD'ku 5 % Xywdkst 7-5% ds lkFk 1 fefy- 3.50 4663( अ) 25-10-23 batSD'ku 2 % ¼,½ $ 1%200000 ¼5 ,elhth@fefy -½ ¼ch½ 1 fefy- 1.05 1577( अ) 31-03-23 dSIlwy 2 fexzk - 1 dSIlwy 3.79 4663( अ) 25-10-23 batSD'ku 2 fexzk - @fefy- 1 fefy- 8.10 4663( अ) 25-10-23 batSD'ku 10 % 1 fefy- 0.19 1577( अ) 31-03-23 /मि.ली. 1 मि.ली. 289.77 4663( अ) 25-10-23 xksyh 250 fexzk - 1 xksyh 2.11 4663( अ) 25-10-23 में) 1 वाईल 723.02 1579( अ) 31-03-23 में) 1 वाईल 952.74 4663( अ) 25-10-23 xksyh 5 fexzk - 1 xksyh 9.43 4663( अ) 25-10-23 batSD'ku 40 fexzk -@ fefy- 1 fefy- 45.67 4663( अ) 25-10-23 batSD'ku 5 fexzk - @fefy- ¼10 fefy - औि अधिर्क iSd½ 1 fefy- 1.63 4663( अ) 25-10-23 dSIlwy 25 fexzk - 1 dSIlwy 4.14 4663( अ) 25-10-23 dSIlwy 50 fexzk - 1 dSIlwy 5.82 4663( अ) 25-10-23 / क़िंएसन 1 मि.ली. 216.82 4663( अ) 25-10-23 मि.ली. 1 मि.ली. 5.92 1574( अ) 31-03-23 मि.ली. 1 मि.ली. 10.88 4663( अ) 25-10-23 dSIlwy 10 fexzk - 1 dSIlwy 0.95 1577( अ) 31-03-23 टोइन dSIlwy 100 fexzk - 1 dSIlwy 8.64 1577( अ) 31-03-23 टोइनvksjy fyD;wbZM 25 fexzk-@5 fefy - 1 fefy- 0.89 4663( अ) 25-10-23 मि.ली. 1 मि.ली. 20.17 1574( अ) 31-03-23 xksyh 20 fexzk - 1 xksyh 4.34 4663( अ) 25-10-23 dSIlwy 10 fexzk - 1 dSIlwy 2.41 1577( अ) 31-03-23 vksjy fyD;wbZM ds fy, ikmMj 20 fexzk - 1 xzke 1.51 1577( अ) 31-03-23 dSIlwy 40 fexzk - 1 dSIlwy 8.45 1577( अ) 31-03-23 ykblsal ds :i esa 1 fefy- 0.15 4663( अ) 25-10-23 batSD'ku 10 vkbZ;w@fefy - 1 fefy- 39.87 1577( अ) 31-03-23 batSD'ku 30 fexzk -@5 fefy-batSD'ku 100 fexzk-@16-7 fefy- 1 fefy- 215.44 1577( अ) 31-03-23 (2 मम.ली.) 1 मि.ली. 3.97 2124( अ) 04-05-23 मि.ली.) 1 मि.ली. 1.60 2125( अ) 04-05-23 Øhe 5 % 1 xzke 1.85 1577( अ) 31-03-23 yks'ku 1 % 1 fefy- 1.00 4663( अ) 25-10-23 Øhe 1 % 1 xzke 1.50 1577( अ) 31-03-23 yks'ku 5 % 1 fefy- @xzke 1.00 4663( अ) 25-10-23 batSD'ku 22 -75 fexzk- @fefy-¼2 fefy-½ 1 fefy- 2.76 4663( अ) 25-10-23 batSD'ku 22 -75 fexzk- @fefy-¼10 fefy -½ 1 fefy- 2.06 1577( अ) 31-03-23 xksyh 300 fexzk - 1 xksyh 6.57 1577( अ) 31-03-23 xksyh 100 fexzk - 1 xksyh 1.76 1577(अ) 31-03-23 xksyh 50 fexzk - 1 xksyh 0.84 1577( अ) 31-03-23 vksjy fyD;wbZM 30 fexzk-@5 fefy - (पी) 1 fefy- 0.35 4663( अ) 25-10-23 vksjy fyD;wbZM 125 fexzk-@5 fefy - (पी) 1 fefy- 1.10 4663( अ) 25-10-23 dSIlwy 300 fexzk - 1 dSIlwy 4.65 1577( अ) 31-03-23 dSIlwy 100 fexzk - 1 dSIlwy 1.83 4663( अ) 25-10-23 xksyh 10 fe xzk- 1 xksyh 14.54 1577( अ) 31-03-23 batSD'ku 40 vkbZ;w@fefy - 1 fefy- 16.99 4663( अ) 25-10-23 xksyh 2-5 fexzk- 1 xksyh 1.75 4663( अ) 25-10-23 dSIlwy 40 fexzk - 1 dSIlwy 4.25 4663( अ) 25-10-23 xksyh 10 fexzk - 1 xksyh 0.11 1577( अ) 31-03-23 573 र्कुनेनbatSD'ku 300 fexzk -@ fefy- 1 fefy- 9.50 4663( अ) 25-10-23 dSIlwy 2-5 fexzk- 1 dSIlwy 4.66 1577( अ) 31-03-23 dSIlwy 5 fexzk - 1 dSIlwy 7.19 4663( अ) 25-10-23 मि.ली.) 1 मि.ली. 0.68 1574( अ) 31-03-23 (3%) 1 ग्राम 2.06 1579( अ) 31-03-23 मलक़ुड 1 fefy- 31.17 4663( अ) 25-10-23 8.4% 1 मि.ली. 1.35 4663( अ) 25-10-23 अनुिाि) 7-5% 1 fefy- 1.01 4663( अ) 25-10-23 batSD'ku ds fy, ikmMj 3 fexzk- 1 वाईल- 1359.00 4663( अ) 25-10-23 आईयू 1 वाईल 1877.33 1574( अ) 31-03-23 /मि.ली. 1 मि.ली. 5.21 2540( अ) 08-06-23 वाईल 1 वाईल 50389.69 4663( अ) 25-10-23 वाईल 1 वाईल 36910.02 4663( अ) 25-10-23 ( जमली) 1 वाईल - 25.53 1577( अ) 31-03-23 ¼0-5 fefy-½ 12.47 4663( अ) 25-10-23 dSIlwy 50 fexzk - 1 dSIlwy 4.82 1577( अ) 31-03-23 dSIlwy 100 fexzk - 1 dSIlwy 9.04 4663( अ) 25-10-23 xksyh 50000 vkbZ;w िट्रहत) 1 xksyh 0.73 4663( अ) 25-10-23 batSD'ku 50000 vkbZ;w@fefy - 1 fefy- 2.26 1577( अ) 31-03-23 xksyh 300 fexzk - 1 xksyh 13.59 938(अ) 28-02-24 batSD'ku ds fy, ikmMj 12 yk[k ;wfuV 1 वाईल 19.81 938(अ) 28-02-24 batSD'ku ds fy, ikmMj 6 yk[k ;wfuV 1 वाईल 11.6 9 938(अ) 28-02-24 batSD'ku 50 ,elhth@fefy - 1 fefy- 20.96 938(अ) 28-02-24 dSIlwy 5 fexzk - 1 dSIlwy 5.04 938(अ) 28-02-24 batSD'ku 20 fexzk - @fefy- 1 fefy- 11.24 938(अ) 28-02-24 dSIlwy 40 fexzk - 1 dSIlwy 5.67 938(अ) 28-02-24 batSD'ku ds fy, ikmMj 500 fexzk - 1 वाईल 188.65 938(अ) 28-02-24 ykbvksfQykftM ikWyhosysaV ऐज मम.ली. 665.26 938(अ) 28-02-24 lksyqcy@fyD;wbM ikWyhosysaV ऐज मम.ली. 428.67 938(अ) 28-02-24 xksyh 2 fexzk - 1 xksyh 31.16 938(अ) 28-02-24 xksyh 5 fexzk - 1 xksyh 77.21 938(अ) 28-02-24 xksyh 2 fexzk - 1 xksyh 91.34 938(अ) 28-02-24 xksyh 5 fexzk - 1 xksyh 86.04 938(अ) 28-02-24 batSD'ku 1 fexzk - @fefy- 1 fefy- 30.54 938(अ) 28-02-24 batSD'ku 250 fexzk -@5 fefy- 1 fefy- 2.04 938(अ) 28-02-24 0.67 938(अ) 28-02-24 bugsys”ku ¼,eMhvkbZ ½ 100 ,elhth@Mkst 1 ehVj Mkst 1.41 938(अ) 28-02-24 bugsys”ku ¼,eMhvkbZ ½ 200 ,elhth@Mkst 1 ehVj Mkst 2.03 938(अ) 28-02-24 bugsys”ku ¼MhihvkbZ½ 200 ,elhth@Mkst 1 Mkst 3.33 938(अ) 28-02-24 usty Lizs 100 ,elhth@Mkst 1 Mkst 0.81 938(अ) 28-02-24 bugsys”ku ¼,eMhvkbZ ½ 100 ,elhth ¼,½ $ 6 ,elhth ¼ch½ 1 ehVj Mkst 2.12 938(अ) 28-02-24 bugsys”ku ¼MhihvkbZ½ 100 ,elhth ¼,½ $ 6 ,elhth ¼ch½ 1 Mkst 4.32 938(अ) 28-02-24 bugsys”ku ¼MhihvkbZ½ 200 ,elhth ¼,½ $ 6 ,elhth ¼ch½ 1 Mkst 5.72 938(अ) 28-02-24 bugsys”ku ¼MhihvkbZ½ 400 ,elhth ¼,½ $ 6 ,elhth ¼ch½ 1 Mkst 6.62 938(अ) 28-02-24 मीटि 17.02 1580(अ) 31-03-23 मीटि 28.83 1580( अ) 31-03-23 मीटि 285.98 4663( अ) 25-10-23 - ( 0.00551 % ) 11(3) (5) a b 0.00551 (5) V (4) (1) u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals ) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY ) ORDER New Delhi, the 26th March , 2024 S.O. 1547(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authorit y, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and stren gth Unit Ceiling price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O., No. & Date (1) (2) (3) (4) (5) (6a) (6b) 1 6-Mercaptopurine Tablet 50mg 1 Tablet 5.26 4663(E) 25-10-23 2 Abacavir Tablet 300 mg 1 Tablet 48.59 1574(E) 31-03-23 3 Abacav ir (A) + Lamivudine (B) Tablet 600mg (A) +300mg (B) 1 Tablet 72.32 4663(E) 25-10-23 4 Acetazolamide Tablet 250mg 1 Tablet 4.06 4663(E) 25-10-23 5 Acetazolamide Capsule 250mg 1 Capsule 5.05 4663(E) 25-10-23 6 Acetylsalicylic acid Enteric coated Tablet 75 mg 1 Tablet 0.35 4663(E) 25-10-23 7 Acetylsalicylic acid Conventional/Effer vescent/Dispersible/ Enteric coated Tablets 150 mg 1 Tablet 0.71 4663(E) 25-10-23 8 Actinomycin D Powder for Injection 0.5mg 1 Vial 331.03 4663(E) 25-10-23 9 Acyclovir Tablet 400mg 1 Tablet 13.66 4663(E) 25-10-23 10 Acyclovir Tablet 200mg 1 Tablet 7.61 1574(E) 31-03-23 11 Acyclovir Powder for Injection 250 mg 1 Vial 426.40 4663(E) 25-10-23 12 Acyclovir Powder for Injection 500 mg 1 Vial 528.45 4663(E) 25-10-23 13 Acyclovir Tablet 800mg 1 Tablet 37.66 1574(E) 31-03-23 14 Acyclovir Ointment 3% 1 GM 11.67 1574(E) 31-03-23 15 Acyclovir Oral liquid 400mg/5mL (p) 1 ML 1.36 4663(E) 25-10-23 16 Adenosine Injection 3mg/mL 1 ML 92.86 4663(E) 25-10-23 17 Adrenaline Injection1mg/mL 1 ML 12.23 1574(E) 31-03-23 18 Albendazole Oral liquid 200mg/5mL(p) 1 ML 1.79 1577(E) 31-03-23 19 Albendazole Tablet 400mg 1 Tablet 7.04 1577(E) 31-03-23 20 Albendazole Chewable Tablet 400mg 1 Tablet 8.13 4663(E) 25-10-23 21 Allopurinol Tablet 300mg 1 Tablet 5.63 4663(E) 25-10-23 22 Allopurinol Tablet 100mg 1 Tablet 1.89 1574(E) 31-03-23 23 Alprostadil Injection 0.5mg/mL 1 ML 6106.75 1574(E) 31-03-23 24 Amikacin Injection 250mg/mL 1 ML 54.17 4663(E) 25-10-23 25 Amiodarone Tablet 200mg 1 Tablet 11.51 1574(E) 31-03-23 26 Amiodarone Tablet 100mg 1 Tablet 6.14 1574(E) 31-03-23 27 Amiodarone Injection 50mg/mL 1 ML 21.13 1574(E) 31-03-23 28 Amitriptyline Tablet 50mg 1 Tablet 5.99 4663(E) 25-10-23 29 Amitriptyline Tablet 75mg 1 Tablet 5.45 4663(E) 25-10-23 30 Amitriptyline Tablet 25mg 1 Tablet 2.49 4663(E) 25-10-23 31 Amitriptyline Tablet 10mg 1 Tablet 2.39 4663(E) 25-10-23 32 Amlodipine Tablet 2.5mg 1 Tablet 1.79 1574(E) 31-03-23 33 Amlodipine Tablet 5mg 1 Tablet 2.50 1574(E) 31-03-23 34 Amlodipine Tablet 10mg 1 Tablet 5.45 4663(E) 25-10-23 35 Amoxicillin Capsule 250mg 1 Capsule 2.44 1574(E) 31-03-23 36 Amoxicillin Capsule 500mg 1 Capsule 7.36 4663(E) 25-10-23 37 Amoxicillin Oral liquid 250 mg/5 mL (p) 1 ML 1.56 4663(E) 25-10-23 38 Amo xicillin Powder for Injection 250 mg 1 Vial 24.79 1578(E) 31-03-23 39 Amoxicillin Powder for Injection 500 mg 1 Vial 54.65 4663(E) 25-10-23 40 Amoxicillin Oral liquid 125 mg/5 mL (p) 1 ML 1.02 1579(E) 31-03-23 41 Amoxicillin (A) + Clavulanic acid (B) Powder for Injection 1 g (A) +200mg (B) 1 Vial 140.66 4663(E) 25-10-23 42 Amoxicillin (A) + Clavulanic acid (B) Powder for Injection 500mg (A) + 100mg (B) 1 Vial 101.35 4663(E) 25-10-23 43 Amoxicillin (A) + Clavulanic acid (B) Dry Syrup 125mg (A) + 31.25 (B)/5mL(p) 1 ML 2.05 1574(E) 31-03-23 44 Amoxicillin (A) +Clavulanic acid (B) Tablet 500 mg (A) + 125 mg (B) 1 Tablet 18.30 4663(E) 25-10-23 45 Amoxicillin (A) +Clavulanic acid (B) Oral liquid 200 mg (A) + 28.5mg(B)/5 mL(p) 1 ML 2.02 4663(E) 25-10-23 46 Amphotericin B Amphotericin B(conventional) - Injection 50mg/vial 1 Vial 227.40 1577(E) 31-03-23 47 Ampicillin Powder for Injection 500 mg 1 Vial 14.25 1574(E) 31-03-23 48 Artemether (A) + Lumefantrine (B) Tablet 40 mg (A) + 240 mg (B) 1 Tablet 18.04 1574(E) 31-03-23 49 Artemether (A) +Lumefantrine(B) Tablet 80mg(A)+480mg(B ) 1 Tablet 25.51 4663(E) 25-10-23 50 Artemether (A) +Lumefantrine (B) Tablet 20 mg (A) + 120 mg (B) 1 Tablet 12.65 4663(E) 25-10-23 51 Artesunate Powder for Injection 60 mg 1 Vial 244.73 4663(E) 25-10-23 52 Artesunate Powder for Injection 120mg 1 Vial 454.44 4663(E) 25-10-23 53 Artesunate (A) + Sulphadoxine -Pyrimethamine (B) Combi pack (A+B) 1 Tablet 50mg (A) + 1Tablet (500mg + 25mg) (B) 1 Combi Pack 22.55 4663(E) 25-10-23 54 Ascorbic acid (Vitamin C) Tablet 100mg 1 Tablet 0.24 4663(E) 25-10-23 55 Ascorbic acid (Vitamin C) Tablet 500mg 1 Tablet 1.48 1577(E) 31-03-23 56 Atazanavir (A) +Ritonavir(B) Tablet 300mg(A) + Tablet 100mg(B) 1 Tablet 99.83 1574(E) 31-03-23 57 Atorvastat in Tablet 40mg 1 Tablet 19.30 4663(E) 25-10-23 58 Atorvastatin Tablet 20mg 1 Tablet 12.56 4663(E) 25-10-23 59 Atorvastatin Tablet 10mg 1 Tablet 4.94 1574(E) 31-03-23 60 Atorvastatin Tablet 80mg 1 Tablet 40.58 4663(E) 25-10-23 61 Atracurium Injectio n 10 mg/ml 1 ML 16.98 4663(E) 25-10-23 62 Atropine Drops 1% 1 ML 3.94 4663(E) 25-10-23 63 Atropine Ointment 1% 1 GM 4.71 4663(E) 25-10-23 64 Atropine Injection 0.6mg/mL 1 ML 4.57 1574(E) 31-03-23 65 Azathioprine Tablet 50mg 1 Tablet 11.26 4663(E) 25-10-23 66 Azathioprine Tablet 25mg(p) 1 Tablet 7.24 1578(E) 31-03-23 67 Azithromycin Powder for Injection 500mg 1 Vial 204.72 1574(E) 31-03-23 68 Azithromycin Tablet 250mg 1 Tablet 11.65 4663(E) 25-10-23 69 Azithromycin Tablet 500mg 1 Tablet 23.57 4663(E) 25-10-23 70 Azithromycin Oral liquid 200 mg/5 mL (p) 1 ML 3.41 4663(E) 25-10-23 71 Azithromycin Capsule250mg 1 Capsule 10.62 4663(E) 25-10-23 72 Azithromycin Tablet 1000mg 1 Tablet 57.78 4663(E) 25-10-23 73 Azithromycin Capsule 500mg 1 Capsule 19.03 2124(E) 04-05-23 74 Baclofen Tablet 20mg 1 Tablet 16.28 1574(E) 31-03-23 75 Baclofen Tablet 10mg 1 Tablet 11.90 4663(E) 25-10-23 76 Baclofen Tablet 5mg 1 Tablet 6.37 4663(E) 25-10-23 77 Bendamustine hydrochloride Injection 100 mg/vial 1 Vial 4946.80 1574(E) 31-03-23 78 Benzoyl peroxide Gel 2.5 1 GM 3.62 1574(E) 31-03-23 79 Benzoyl peroxide Gel 5 % 1 GM 7.97 1574(E) 31-03-23 80 Benzoyl peroxide Gel 3.5% 1 GM 10.11 1578(E) 31-03-23 81 Betamethasone Injection 4mg/mL 1 ML 4.74 1577(E) 31-03-23 82 Betamethasone valerate Cream 0.05% 1 GM 0.67 1574(E) 31-03-23 83 Betamethasone valerate Cream 0.1% 1 GM 1.04 1574(E) 31-03-23 84 Bicalutamide Tablet 50mg 1 Tablet 43.30 1574(E) 31-03-23 85 Bisacodyl Tablet 5mg 1 Tablet 1.17 4663(E) 25-10-23 86 Bisaco dyl Suppository 5mg 1 Suppository 9.98 4663(E) 25-10-23 87 Bleomycin Powder for Injection 15units 1 Vial 677.41 1574(E) 31-03-23 88 Bortezomib Powder for Injection 2mg 1 Vial 5260.50 4663(E) 25-10-23 89 Budesonide Respirator solution for use in nebulize r 0.5mg/mL 1 ML 11.90 4663(E) 25-10-23 90 Budesonide Respirator solution for use in nebulizer 1mg/mL 1 ML 13.14 1577(E) 31-03-23 91 Bupivacaine Injection 0.5 % with 7.5 % glucose 1 ML 7.39 4663(E) 25-10-23 92 Bupivacaine Injection 0.5 % 1 ML 4.42 4663(E ) 25-10-23 93 Bupivacaine Injection 0.25% 1 ML 2.83 4663(E) 25-10-23 94 Buprenorphine Tablet (Sub - lingual)0.4mg 1 Tablet 9.43 4663(E) 25-10-23 95 Buprenorphine (A) +Naloxone (B) Tablet (Sub - lingual) 2mg(A)+0.5mg(B) 1 Tablet 36.98 4663(E) 25-10-23 96 Buprenorphine (A) +Naloxone (B) Table t (Sub - lingual) 0.4mg(A)+0.1mg (B) 1 Tablet 11.82 4663(E) 25-10-23 97 Caffeine Oral liquid 20 mg/mL 1 ML 245.68 1574(E) 31-03-23 98 Caffeine Injection 20mg/mL Per ML 250.50 1577(E) 31-03-23 99 Calamine Lotion (As per IP) 1 ML 0.95 1577(E) 31-03-23 100 Calcium folinate Tablet 15mg 1 Tablet 47.54 4663(E) 25-10-23 101 Capecitabine Tablet 500mg 1 Tablet 112.73 4663(E) 25-10-23 102 Carbamazepine Modified Release – Tablet 200mg 1 Tablet 2.40 4663(E) 25-10-23 103 Carbamazepine Modified Release – Tablet 400mg 1 Tablet 4.66 1574(E) 31-03-23 104 Carbamazepine Tablet 400mg 1 Tablet 3.55 1574(E) 31-03-23 105 Carbamazepine Tablet 200mg 1 Tablet 1.57 4663(E) 25-10-23 106 Carbamazepine Oral liquid 100mg/5mL(p) 1 ML 0.31 1574(E) 31-03-23 107 Carbamazepine Tablet 100mg 1 Tablet 1.07 4663(E) 25-10-23 108 Carbimazole Tablet 10mg 1 Tablet 4.26 1574(E) 31-03-23 109 Carbimazole Tablet 5mg 1 Tablet 2.19 4663(E) 25-10-23 110 Carbimazole Tablet 20mg 1 Tablet 13.87 4663(E) 25-10-23 111 Carboplatin Injection 10mg/mL 1 ML 59.07 4663(E) 25-10-23 112 Carboxymethyl cellulose Drops 0.5% 1 ML 12.30 4663(E) 25-10-23 113 Carboxymethyl cellulose Drops 1% 1 ML 16.58 1574(E) 31-03-23 114 Cefadroxil Tablet 500mg 1 Tablet 4.47 1574( E) 31-03-23 115 Cefadroxil Oral liquid 125mg/5mL(p) 1 ML 0.68 1574(E) 31-03-23 116 Cefixime Tablet 400mg 1 Tablet 22.10 4663(E) 25-10-23 117 Cefixime Tablet 200mg 1 Tablet 9.78 4663(E) 25-10-23 118 Cefixime Oral liquid 50 mg/5 mL (p) 1 ML 1.63 4663(E) 25-10-23 119 Cefixime Oral liquid 100mg/5mL(p) 1 ML 2.39 4663(E) 25-10-23 120 Cefixime Capsule 200mg 1 Capsule 14.68 4663(E) 25-10-23 121 Cefotaxime Powder for Injection 250 mg 1 Vial 17.72 4663(E) 25-10-23 122 Cefotaxime Powder for Injection 500 mg 1 Vial 24.38 4663(E) 25-10-23 123 Cefotaxime Powder for Injection 1000mg 1 Vial 39.96 1574(E) 31-03-23 124 Ceftazidime Powder for Injection 1000mg 1 Vial 227.02 1574(E) 31-03-23 125 Ceftazidime Powder for Injection 250 mg 1 Vial 79.07 4663(E) 25-10-23 126 Ceftriaxone Powder for Injection 500 mg 1 Vial 50.28 4663(E) 25-10-23 127 Ceftriaxone Powder for Injection 250 mg 1 Vial 28.34 1574(E) 31-03-23 128 Ceftriaxone Powder for Injection 1000mg 1 Vial 62.38 1574(E) 31-03-23 129 Ceftriaxone Powder for Injec tion 2000mg 1 Vial 138.12 1574(E) 31-03-23 130 Cefuroxime Tablet 500mg 1 Tablet 51.43 1578(E) 31-03-23 131 Cefuroxime Injection 1500 mg 1 Vial 338.76 1579(E) 31-03-23 132 Cetirizine Tablet 10mg 1 Tablet 1.88 1574(E) 31-03-23 133 Cetirizine Oral liquid 5mg/5mL(p) 1 ML 0.66 1574(E) 31-03-23 134 Chloroquine Tablet 150 mg 1 Tablet 1.17 4663(E) 25-10-23 135 Chloroquine Oral liquid 50mg/5mL 1 ML 0.34 4663(E) 25-10-23 136 Cholecalciferol Tablet 1000 IU 1 Tablet 4.31 4663(E) 25-10-23 137 Cholecalciferol Oral liquid 400 IU/mL 1 ML 2.61 1574(E) 31-03-23 138 Cholecalciferol Solid oral dosage form 60000 IU Tablets 1 Tablet 22.50 1574(E) 31-03-23 139 Cholecalciferol Capsule 60000 IU 1 Capsule 30.78 4663(E) 25-10-23 140 Cholecalciferol Capsule 1000 IU 1 Capsule 4.89 4663(E) 25-10-23 141 Cholecalciferol Sache t/ Granuels / Powder 60000 IU 1 GM 33.98 1578(E) 31-03-23 142 Ciprofloxacin Tablet 250mg 1 tablet 2.20 4663(E) 25-10-23 143 Ciprofloxacin Tablet 500mg 1 tablet 4.25 4663(E) 25-10-23 144 Ciprofloxaci n Drops 0.3 % 1 ML 1.54 4663(E) 25-10-23 145 Ciprofloxacin Injection 200mg/100mL 1 ML 0.20 1574(E) 31-03-23 146 Ciprofloxacin Oral liquid 250mg/5mL(p) 1 ML 0.74 1577(E) 31-03-23 147 Ciprofloxacin Ointment 0.3% 1 GM 1.29 4663(E) 25-10-23 148 Cisplatin Injection 1mg/mL 1 ML 7.09 4663(E) 25-10-23 149 Clarithromycin Tablet 250mg 1 Tablet 23.89 1574(E) 31-03-23 150 Clarithromycin Tablet 500mg 1 Tablet 39.84 4663(E) 25-10-23 151 Clarithromycin Oral liquid 125mg/5mL(p) 1 ML 4.61 4663(E) 25-10-23 152 Clindamycin Capsule 150mg 1 Capsule 16.36 4663(E) 25-10-23 153 Clindamycin Capsule 300mg 1 Capsule 28.37 4663(E) 25-10-23 154 Clindamycin Tablet 300mg 1 Tablet 18.97 1574(E) 31-03-23 155 Clindamycin Injection150mg/mL 1 ML 60.60 1579(E) 31-03-23 156 Cloba zam Tablet 5mg 1 Tablet 5.73 4663(E) 25-10-23 157 Clobazam Tablet 10mg 1 Tablet 9.84 1574(E) 31-03-23 158 Clofazimine Capsule100mg 1 Capsule 3.98 2540(E) 08-06-23 159 Clofazimine Capsule 50mg 1 Capsule 2.11 2540(E) 08-06-23 160 Clomiphene citrate Capsule 50mg 1 Capsule 27.37 2124(E) 04-05-23 161 Clomiphene citrate Capsule 100 mg 1 Capsule 51.14 2124(E) 04-05-23 162 Clomiphene citrate Tablet 100 mg 1 Tablet 13.95 4663(E) 25-10-23 163 Clomiphene citrate Tablet 50mg 1 Tablet 8.84 4663(E) 25-10-23 164 Clomipramine Tablet 10 mg 1 Tablet 2.85 4663(E) 25-10-23 165 Clomipramine Tablet 25 mg 1 Tablet 6.22 1577(E) 31-03-23 166 Clomipramine Tablet 75 mg 1 Tablet 16.46 4663(E) 25-10-23 167 Clonazepam Tablet 0.25mg 1 Tablet 2.02 4663(E) 25-10-23 168 Clonazepam Tablet 0.5mg 1 Tablet 3.45 1574(E) 31-03-23 169 Clonazepam Tablet 1mg 1 Tablet 4.77 4663(E) 25-10-23 170 Clopidogrel Tablet 75mg 1 Tablet 6.66 1574(E) 31-03-23 171 Clopidogrel Tablet 150 mg 1 Tablet 20.48 1574(E) 31-03-23 172 Clotrimazole Lotio n 1% 1 ML 3.89 1577(E) 31-03-23 173 Clotrimazole Pessary 100mg 1 Pessary 10.01 1577(E) 31-03-23 174 Clotrimazole Drops 1% 1 ML 3.37 1577(E) 31-03-23 175 Clotrimazole Cream1% 1 GM 3.00 1577(E) 31-03-23 176 Clozapine Tablet 25mg 1 Tablet 2.78 1574(E) 31-03-23 177 Clozapine Tablet 50mg 1 Tablet 5.19 1574(E) 31-03-23 178 Clozapine Tablet 100 mg 1 Tablet 8.45 1574(E) 31-03-23 179 Colchicine Tablet 0.5mg 1 Tablet 3.26 1574(E) 31-03-23 180 Co-trimoxazole [Sulphamethoxazole (A) +Trimethoprim(B)]* Tablet 400 mg (A) + 80 mg (B) 1 Tablet 0.90 4663(E) 25-10-23 181 Co-trimoxazole [Sulphamethoxazole (A)+Trimethoprim (B)] Tablet 800mg (A) + 160 mg (B) 1 Tablet 2.30 4886(E) 10-11-23 182 Co-trimoxazole [Sulphamethoxazole(A) +Trimethoprim(B)]* Oral liquid 200 mg (A) + 40 mg(B)/5mL(p) 1 ML 0.35 4663(E) 25-10-23 183 Cyclophosphamide Powder for Injection 500mg 1 Vial 73.48 1574(E) 31-03-23 184 Cyclophosphamide Tablet 50mg 1 Tablet 3.73 1577(E) 31-03-23 185 Cycloserine Capsule250mg 1 Capsule 59.19 4663(E) 25-10-23 186 Cycloserine Tablet 250mg 1 Tablet 46.01 1577(E) 31-03-23 187 Cyclosporine Capsule 25 mg 1 Capsule 28.04 1574(E) 31-03-23 188 Cyclosporine Oral liquid 100mg/mL(p) 1 ML 80.58 1574(E) 31-03-23 189 Cyclosporine Capsule 50 mg 1 Capsule 55.11 4663(E) 25-10-23 190 Cyclosporine Capsule 100mg 1 Capsule 103.12 4663(E) 25-10-23 191 Cytosine arabinoside Injection 1000mg/vial 1 Vial 1130.33 4663(E) 25-10-23 192 Cytosine arabinoside Injection 100mg/vial 1 Vial 139.59 1574(E) 31-03-23 193 Cytosine arabinoside Injection 500mg/vial 1 Vial 536.33 1574(E) 31-03-23 194 Dabigatran Capsule 110mg 1 Capsule 31.81 2822(E) 28-06-23 195 Dabigatran Capsule 150mg 1 Capsule 35.59 2822(E) 28-06-23 196 Dacarbazine Powder for Injection 200mg 1 Vial 381.75 4663(E) 25-10-23 197 Dacarbazine Powder for Injection 500mg 1 Vial 518.83 4663(E) 25-10-23 198 Daclatasvir Tablet 60mg 1 Tablet 199.97 4663(E) 25-10-23 199 Dapsone Tablet 100 mg 1 Tablet 0.41 2540(E) 08-06-23 200 Darunavir Tablet 600mg 1 Tablet 154.44 4663(E) 25-10-23 201 Dexamethasone Tablet 0.5mg 1 Tablet 0.22 1574(E) 31-03-23 202 Dexamethasone Tablet 4 mg 1 Tablet 4.62 4663(E) 25-10-23 203 Dexamethasone Injection 4mg/mL (2 ML) 1 ML 5.09 2124(E) 04-05-23 204 Dexamethasone Injection 4mg/mL (5 ML) 1 ML 2.57 2125(E) 04-05-23 205 Dexamethasone Injection 4mg/mL (Pack of 10ML) 1 ML 1.57 4663(E) 25-10-23 206 Dexamethasone Injection 4mg/mL (Pack of 20 ML) 1 ML 1.35 4663(E) 25-10-23 207 Dexamethasone Injection 4mg/mL (Pack of 30ML) 1 ML 0.90 4663(E) 25-10-23 208 Diazepam Tablet 5 mg 1 Tablet 1.63 4663(E) 25-10-23 209 Diazepam Injection 5mg/mL 1 ML 5.54 4663(E) 25-10-23 210 Diazepam Tablet 2 mg 1 Tablet 1.44 4663(E) 25-10-23 211 Diazepam Suppository 5mg 1 Suppository 6.19 4663(E) 25-10-23 212 Diclofenac Tablet 50m g 1 Tablet 2.05 1574(E) 31-03-23 213 Diclofenac Injection 25mg/mL 1 ML 1.69 1574(E) 31-03-23 214 Dicyclomine Injection 10mg/mL (Less than 10ML Pack) 1 ML 3.32 4663(E) 25-10-23 215 Dicyclomine Injection 10mg/mL (10 ML & more pack)) 1 ML 2.10 4663(E) 25-10-23 216 Diethylcarbamazine (DEC) Tablet 100mg 1 Tablet 1.67 1574(E) 31-03-23 217 Diethylcarbamazine (DEC) Tablet 50mg 1 Tablet 0.56 1574(E) 31-03-23 218 Diethylcarbamazine (DEC) Oral liquid 120mg/5mL(p) 1 ML 0.48 1574(E) 31-03-23 219 Digoxin Tablet 0 .25mg 1 Tablet 1.33 1574(E) 31-03-23 220 Digoxin Oral liquid0.05mg/mL 1 ML 1.47 4663(E) 25-10-23 221 Digoxin Injection 0.25mg/mL 1 ML 3.87 4663(E) 25-10-23 222 Diltiazem Tablet 60mg 1 Tablet 5.46 1574(E) 31-03-23 223 Diltiazem Tablet 30mg 1 Tablet 2.68 4663(E) 25-10-23 224 Diltiazem Injection 5mg/mL 1 ML 3.50 4663(E) 25-10-23 225 Dinoprostone Gel 0.5mg 1 GM 84.72 4663(E) 25-10-23 226 Dobutamine Injection 50 mg/ml 1 ML 9.03 4663(E) 25-10-23 227 Docetaxel Powder for Injection 20mg 1 Vial 2868.39 1574( E) 31-03-23 228 Docetaxel Powder for Injection 80mg 1 Vial 10333.69 1574(E) 31-03-23 229 Dolutegravir Tablet 50mg 1 Tablet 112.79 1574(E) 31-03-23 230 Domperidone Tablet 10mg 1 Tablet 2.31 4663(E) 25-10-23 231 Domperidone Oral Liquid 1mg/mL 1 ML 1.24 1574(E) 31-03-23 232 Donepezil Tablet 10mg 1 Tablet 17.46 4663(E) 25-10-23 233 Donepezil Tablet 5mg 1 Tablet 12.11 4663(E) 25-10-23 234 Dopamine Injection 40mg/mL 1 ML 4.77 4663(E) 25-10-23 235 Doxorubicin Injection2mg/mL 1 ML 31.75 1577(E) 31-03-23 236 Doxycycline Capsule 100mg 1 Capsule 3.08 1574(E) 31-03-23 237 Doxycycline Tablet100mg 1 Tablet 1.22 1577(E) 31-03-23 238 Doxycycline Powder for Injection 100 mg 1 Vial 502.64 4663(E) 25-10-23 239 D-Penicillamine Capsule 250 mg 1 Capsule 15.65 1574( E) 31-03-23 240 DPT+ Hib+ Hep B Vaccine As licensed Per 0.1 ML 75.65 4663(E) 25-10-23 241 Efavirenz Tablet 600mg 1 Tablet 70.59 1574(E) 31-03-23 242 Efavirenz Tablet 200 mg (p) 1 Tablet 22.54 4663(E) 25-10-23 243 Efavirenz Capsule 200 mg 1 Capsule 21.98 2124(E) 04-05-23 244 Enalapril Tablet 5mg 1 Tablet 3.70 1574(E) 31-03-23 245 Enalapril Tablet 2.5mg 1 Tablet 2.19 4663(E) 25-10-23 246 Enoxaparin Injection40mg/0.4 mL , injection 60mg/0.6 ml 0.10 ML 111.99 4663(E) 25-10-23 247 Entecavir Tablet 1mg 1 Tablet 130.24 4663(E) 25-10-23 248 Entecavir Tablet 0.5mg 1 Tablet 84.44 4663(E) 25-10-23 249 Erythropoietin Injection 2000IU/mL 1 ML 549.58 1574(E) 31-03-23 250 Erythropoietin Injection 10000 IU/mL 1 ML 1969.11 1574(E) 31-03-23 251 Escitalopram Tablet 5mg 1 Tablet 5.02 1574(E) 31-03-23 252 Escitalopram Tablet 10mg 1 Tablet 9.00 1574(E) 31-03-23 253 Escitalopram Tablet 20mg 1 Tablet 14.36 1574(E) 31-03-23 254 Esmolol Injection10 mg/mL 1 ML 26.38 1577(E) 31-03-23 255 Ethambutol Tablet 600mg 1 Tablet 4.08 1574(E) 31-03-23 256 Ethambutol Tablet 800mg 1 Tablet 4.96 4663(E) 25-10-23 257 Ethambutol Tablet 400mg 1 Tablet 2.61 1574(E) 31-03-23 258 Ethambutol Tablet 200mg 1 Tablet 1.14 1577(E) 31-03-23 259 Ethinylestradiol (A)+ Levonorgestrel (B) Tablet 0.03mg(A) + Tablet 0.15mg(B) 1 Tablet 3.17 1574(E) 31-03-23 260 Ethionamide Tablet 250mg 1 Tablet 14.81 1574(E) 31-03-23 261 Etoposide Capsule 50mg 1 Capsule 56.63 1574(E) 31-03-23 262 Etoposide Injection 20mg/mL 1 ML 34.51 1574(E) 31-03-23 263 Filgrastim Injection 300mcg 1 Vial 1159.97 1574(E) 31-03-23 264 Fluconazole Tablet 400mg 1 Tablet 29.75 4663(E) 25-10-23 265 Fluconazole Tablet 200mg 1 Tablet 17.46 4663(E) 25-10-23 266 Fluconazole Tablet 100mg 1 Tablet 7.62 1574(E) 31-03-23 267 Flucon azole Tablet 150mg 1 Tablet 12.06 1574(E) 31-03-23 268 Fluconazole Tablet 50mg 1 Tablet 9.68 4663(E) 25-10-23 269 Fluconazole Capsule 200mg 1 Capsule 40.11 4663(E) 25-10-23 270 Fluconazole Capsule 150mg 1 Capsule 19.22 4663(E) 25-10-23 271 Fluconazole Injection 200mg/100mL Per 100 ML Vial 92.33 1577(E) 31-03-23 272 Fluconazole Capsule 100mg 1 Capsule 21.40 2124(E) 04-05-23 273 Fludrocortisone Tablet 0.1mg 1 Tablet 13.20 2541(E) 08-06-23 274 Flunarizine Tablet 5mg 1 Tablet 2.48 4663(E) 25-10-23 275 Flunarizine Tablet 10mg 1 Tablet 4.82 1574(E) 31-03-23 276 Fluoxetine Capsule 20 mg 1 Capsule 3.99 1574(E) 31-03-23 277 Fluoxetine Capsule 60 mg 1 Capsule 11.10 1574(E) 31-03-23 278 Fluoxetine Capsule 40 mg 1 Capsule 6.49 1574(E) 31-03-23 279 Fluoxe tine Capsule 10 mg 1 Capsule 3.32 4663(E) 25-10-23 280 Fluoxetine Tablet 10 mg 1 Tablet 2.78 2124(E) 04-05-23 281 Fluoxetine Tablet 40 mg 1 Tablet 5.56 2124(E) 04-05-23 282 Fluoxetine Tablet 60 mg 1 Tablet 8.25 2124(E) 04-05-23 283 Fluoxetine Tablet 20 mg 1 Tablet 4.15 2124(E) 04-05-23 284 Fluphenazine Injection 25mg/mL 1 ML 55.26 1574(E) 31-03-23 285 Folic Acid Tablet 5 mg 1 Tablet 1.51 1574(E) 31-03-23 286 Framycetin Cream 1 % 1 GM 1.66 2541(E) 08-06-23 287 Furosemide Tablet 40mg 1 Tablet 0.91 4663(E) 25-10-23 288 Furosemide Injection 10mg/mL 1 ML 2.99 1574(E) 31-03-23 289 Furosemide Oral liquid 10mg/mL 1 ML 3.32 4663(E) 25-10-23 290 Fusidic acid Cream 2 % 1 GM 9.83 1574(E) 31-03-23 291 Gefitinib Tablet 250mg 1 Tablet 237.14 4663(E) 25-10-23 292 Gemcitabine Powder for Injection 1000mg 1 Vial 5592.55 1574(E) 31-03-23 293 Gemcitabine Powder for Injection 200 mg 1 Vial 1299.80 4663(E) 25-10-23 294 Gentamicin Injection 40mg/mL (1.5 ml) 1 ML 2.90 2125(E) 04-05-23 295 Gentamicin Injection 1 0mg/mL 1 ML 2.41 1574(E) 31-03-23 296 Gentamicin Injection 40mg/mL (Pack of 10ml) 1 ML 1.51 1577(E) 31-03-23 297 Gentamicin Injection 40mg/mL (Pack of 20ml) 1 ML 1.55 4663(E) 25-10-23 298 Gentamicin Injection 40mg/mL Pack of 30ml) 1 ML 1.23 1577(E) 31-03-23 299 Gentamicin Injection 40mg/mL (2ml) 1 ML 4.85 2124(E) 04-05-23 300 Glimepiride Tablet 2mg 1 Tablet 5.80 4663(E) 25-10-23 301 Glimepiride Tablet 1mg 1 Tablet 3.70 1574(E) 31-03-23 302 Glucose Injection 25% 1 ML 0.20 1574(E) 31-03-23 303 Glycerin/glycerol (as mentioned in IP) Topical - Lotion 1 ML 1.23 1579(E) 31-03-23 304 Glycerin/glycerol (as mentioned in IP) Topical - Cream 1 GM 2.37 4663(E) 25-10-23 305 Glyceryl trinitrate Injection 5mg/mL 1 ML 6.19 4663(E) 25-10-23 306 Glyceryl tr initrate Sublingual Tablet 0.5mg 1 Tablet 1.27 4663(E) 25-10-23 307 Glycopyrrolate Injection 0.2mg/mL 1 ML 14.53 1574(E) 31-03-23 308 Griseofulvin Tablet 250mg 1 Tablet 1.77 1574(E) 31-03-23 309 Haloperidol Tablet 5mg 1 Tablet 3.57 4663(E) 25-10-23 310 Haloperidol Tablet 10mg 1 Tablet 4.78 4663(E) 25-10-23 311 Haloperidol Oral liquid 2mg/5mL 1 ML 2.24 1574(E) 31-03-23 312 Haloperidol Injection 5mg/mL 1 ML 6.51 1577(E) 31-03-23 313 Haloperidol Tablet 20mg 1 Tablet 5.36 4663(E) 25-10-23 314 Haloperi dol Tablet 1.5mg 1 Tablet 1.58 1697(E) 12-04-23 315 Halothane Liquid for inhalation 1 ML 6.10 4663(E) 25-10-23 316 Heparin Injection 1000IU/mL 1 ML 21.21 1574(E) 31-03-23 317 Heparin Injection 5000IU/mL 1 ML 59.96 1574(E) 31-03-23 318 Hepatitis B immu noglobulin As Licensed 1 Vial 5498.70 4663(E) 25-10-23 319 Hepatitis B vaccine As Licensed 1 ML 78.82 1577(E) 31-03-23 320 Homatropine Drops 2% 1 ML 6.40 1574(E) 31-03-23 321 Hormone Releasing IUD Contains 52 mg of Levonorgestrel 1 IUD 4103.53 4663(E) 25-10-23 322 Human chorionic gonado tropin Injection 5000 IU 1 Vial 417.47 1574(E) 31-03-23 323 Human chorionic gonado tropin Injection10000IU 1 Vial 928.30 4663(E) 25-10-23 324 Human chorionic gonado tropin Injection2000 IU 1 Vial 343.66 1579(E) 31-03-23 325 Hydrochlorothiazide Tablet 25 mg 1 Tablet 1.75 4663(E) 25-10-23 326 Hydrochlorothiazide Tablet 12.5mg 1 Tablet 1.04 1574(E) 31-03-23 327 Hydrocortisone Powder for Injection 100mg 1 Vial 44.79 1574(E) 31-03-23 328 Hydrocortisone Tablet 10mg 1 Tab let 6.70 1574(E) 31-03-23 329 Hydrocortisone Powder for Injection 200mg 1 Vial 65.60 1574(E) 31-03-23 330 Hydrocortisone Tablet 5mg 1 Tablet 3.12 4663(E) 25-10-23 331 Hydrocortisone Tablet 20mg 1 Tablet 14.89 4663(E) 25-10-23 332 Hydroxy propylmethyl cellulose Injection 2% 1 ML 29.21 4663(E) 25-10-23 333 Hydroxychloroquine Tablet 400mg 1 Tablet 13.80 1574(E) 31-03-23 334 Hydroxychloroquine Tablet 200mg 1 Tablet 6.36 4663(E) 25-10-23 335 Hydroxyurea Capsule 500mg 1 Capsule 12.12 1574(E) 31-03-23 336 Ibuprofen Tablet 200mg 1 Tablet 0.71 4663(E) 25-10-23 337 Ibuprofen Tablet 400mg 1 Tablet 1.20 4663(E) 25-10-23 338 Ibuprofen Oral liquid 100mg/5mL(p) 1 ML 0.22 1574(E) 31-03-23 339 Ifosfamide Powder for Injection 2000mg 1 Vial 643.16 4663(E) 25-10-23 340 Ifosfamide Powder for Injection 1000mg 1 Vial 318.96 1577(E) 31-03-23 341 Imatinib Tablet 100mg 1 Tablet 69.75 1574(E) 31-03-23 342 Imatinib Tablet 400mg 1 Tablet 199.62 1574(E) 31-03-23 343 Imatinib Capsule 100mg 1 Capsule 73.48 1577(E) 31-03-23 344 Insulin (Soluble) Injection 40 IU/ml 1 ml 16.99 4663(E) 25-10-23 345 Insulin Glargine Injection 100 IU/ml 1 ML 203.46 4663(E) 25-10-23 346 Insulin Intermediate Acting (NPH) Injection 40IU/mL 1 ML 16.99 4663(E) 25-10-23 347 Iohexol Injection 300mg iodine/mL 1 ML 16.90 4663(E) 25-10-23 348 Iohexol Injection 350mg iodine/mL 1 ML 14.24 4663(E) 25-10-23 349 Irinotecan HCltrihydrate Solution for injection 20mg/mL 1 ML 964.89 1579(E) 31-03-23 350 Iron sucrose Injection 20mg/mL 1 ML 57.41 4663(E) 25-10-23 351 Isoflurane Liquid for inhalation 1 ML 9.65 1574(E) 31-03-23 352 Isoniazid Tablet 300mg 1 Tablet 1.29 2540(E) 08-06-23 353 Isoniazid Tablet 100mg 1 Tablet 0.65 2540(E) 08-06-23 354 Isosorbide dinitrate Tablet 5mg 1 Tablet 0.82 4663(E) 25-10-23 355 Isosorbide dinitrate Tablet 10mg 1 Tablet 0.81 4663(E) 25-10-23 356 Ispaghula Granules/Husk/Pow der 1 GM 0.94 1574(E) 31-03-23 357 Itraconazole Oral liquid 10mg/mL 1 ML 4.94 1574(E) 31-03-23 358 Itraconazole Capsule 100mg 1 Capsule 16.67 1579(E ) 31-03-23 359 Itraconazole Capsule 200mg 1 Capsule 22.12 1579(E) 31-03-23 360 IUD containing Copper As licensed 1 IUD 281.02 4663(E) 25-10-23 361 Ivermectin Tablet 6 mg 1 Tablet 21.58 1578(E) 31-03-23 362 Ivermectin Tablet 12 mg 1 Tablet 37.37 1578( E) 31-03-23 363 Japanese encephalitis vaccine As licensed (4mcg to 6 mcg) 1 Vial 677.17 2124(E) 04-05-23 364 Japanese encephalitis vaccine As licensed (upto 3 mcg) 1 Vial 518.66 2124(E) 04-05-23 365 Ketamine Injection 50mg/mL 1 ML 12.12 1574(E) 31-03-23 366 Labetalol Injection 5mg/mL 1 ML 49.98 1574(E) 31-03-23 367 Labetalol Tablet 100 mg 1 Tablet 15.16 4663(E) 25-10-23 368 Lactulose Oral liquid 10 g/15mL 1 ML 1.23 1574(E) 31-03-23 369 Lamivudine Tablet 100mg 1 Tablet 10.40 1574(E) 31-03-23 370 Lamivudine Tablet 150mg 1 Tablet 10.86 1574(E) 31-03-23 371 L-Asparaginase Powder for Injection 5000 KU 1 Vial 1034.88 4663(E) 25-10-23 372 L-Asparaginase Powder for Injection 10000KU 1 Vial 1707.74 4663(E) 25-10-23 373 Latanoprost Drops 0.005% 1 ML 232.58 2542(E) 08-06-23 374 Lenalidomide Capsule 5mg 1 Capsule 67.25 1574(E) 31-03-23 375 Lenalidomide Capsule 25 mg 1 Capsule 292.28 4663(E) 25-10-23 376 Letrozole Tablet 2.5mg 1 Tablet 29.32 4663(E) 25-10-23 377 Leuprolide acetate Powder for injectio n 22.5 mg 1 Vial 17081.50 4663(E) 25-10-23 378 Leuprolide acetate Powder for injection 11.25mg 1 Vial 9294.48 4663(E) 25-10-23 379 Leuprolide acetate Powder for injection 3.75 mg 1 Vial 3112.67 1574(E) 31-03-23 380 Levetiracetam Tablet 250mg 1 Tablet 6.30 1574(E) 31-03-23 381 Levetiracetam Tablet 500mg 1 Tablet 12.98 1574(E) 31-03-23 382 Levetiracetam Modified Release Tablet 750mg 1 Tablet 18.30 4663(E) 25-10-23 383 Levetiracetam Tablet 750mg 1 Tablet 19.34 1574(E) 31-03-23 384 Levetiracetam Oral liquid 100 mg/mL (p) 1 ML 3.97 4663(E) 25-10-23 385 Levetiracetam Injection 100mg/mL 1 ML 23.02 4663(E) 25-10-23 386 Levodopa (A) + Carbidopa (B) Modified Release – Tablet 200mg (A) + 50mg (B) 1 Tablet 4.73 1574(E) 31-03-23 387 Levodopa (A) +Carbidopa(B) Tablet 100 mg (A) + 25 mg (B) 1 Tablet 2.58 4663(E) 25-10-23 388 Levodopa (A) +Carbidopa(B) Tablet 100 mg (A) + 10 mg (B) 1 Tablet 1.76 1574(E) 31-03-23 389 Levodopa (A) +Carbidopa(B) Tablet 250mg(A) +25mg(B) 1 Tablet 4.42 4663(E) 25-10-23 390 Levod opa (A) +Carbidopa(B) Modified Release – Tablet 100 mg (A) + 25 mg (B) 1 Tablet 2.79 1574(E) 31-03-23 391 Levofloxacin Tablet 750mg 1 Tablet 12.45 4663(E) 25-10-23 392 Levofloxacin Tablet 250mg 1 Tablet 4.82 1697(E) 12-04-23 393 Levofloxacin Tablet 500m g 1 Tablet 8.99 1697(E) 12-04-23 394 Levothyroxine Tablet 50mcg 1 Tablet 1.03 1574(E) 31-03-23 395 Levothyroxine Tablet 75mcg 1 Tablet 1.44 4663(E) 25-10-23 396 Levothyroxine Tablet 88 mcg 1 Tablet 1.65 4663(E) 25-10-23 397 Levothyroxine Tablet 112 mcg 1 Tablet 1.66 4663(E) 25-10-23 398 Levothyroxine Tablet 25 mcg 1 Tablet 1.45 4663(E) 25-10-23 399 Levothyroxine Tablet 62.5mcg 1 Tablet 1.61 1574(E) 31-03-23 400 Levothyroxine Tablet 12.5mcg 1 Tablet 1.48 1574(E) 31-03-23 401 Levothyroxine Tablet 100mcg 1 Tablet 1.32 1574(E) 31-03-23 402 Levothyroxine Tablet 125mcg 1 Tablet 1.69 1574(E) 31-03-23 403 Levothyroxine Tablet 150 mcg 1 Tablet 1.70 1577(E) 31-03-23 404 Lignocaine Topical forms 2 -5 % 1 GM/ML 1.13 1574(E) 31-03-23 405 Lignocaine Injection 2% 1 ML 1.04 1574(E) 31-03-23 406 Lignocaine Injection 1% 1 ML 8.87 4663(E) 25-10-23 407 Lignocaine Injection 5% with 7.5% glucose 1 ML 3.50 4663(E) 25-10-23 408 Lignocaine (A) +Adrenaline(B) Injection2%(A)+1:2 00000(5 mcg/mL)(B) 1 ML 1.05 1577(E) 31-03-23 409 Linezolid Tablet 600mg 1 Tablet 35.67 4663(E) 25-10-23 410 Linezolid Tablet 300 mg 1 Tablet 22.65 4663(E) 25-10-23 411 Lithium Tablet 300mg 1 Tablet 1.63 4663(E) 25-10-23 412 Loperamide Tablet 2mg 1 Tablet 2.28 4663(E) 25-10-23 413 Loperamide Capsule 2mg 1 Capsule 3.79 4663(E) 25-10-23 414 Lopinavir (A) + Ritonavir(B) Tablet 200 mg (A) + 50mg (B) 1 Tablet 47.97 4663(E) 25-10-23 415 Lorazepam Tablet 1 mg 1 Tablet 2.31 4663(E) 25-10-23 416 Lorazepam Tablet 2 mg 1 Tablet 2.81 1574(E) 31-03-23 417 Lorazepam Injection 2mg/mL 1 ML 8.10 4663(E) 25-10-23 418 Magnesium sulphate Injection 500mg/mL 1 ML 4.87 4663(E) 25-10-23 419 Mannitol Injection 20 % 1 ML 0.35 4663(E) 25-10-23 420 Mannitol Injection 10 % 1 ML 0.19 1577(E) 31-03-23 421 Mebendazole Tablet 100 mg 1 Tablet 2.90 1574(E) 31-03-23 422 Mebendazole Oral liquid 100mg/5mL(p) 1 ML 0.84 1574(E) 31-03-23 423 Medroxyprogesterone acetate Tablet 10 mg 1 Tablet 6.25 4663(E) 25-10-23 424 Medroxyprogesterone acetate Injection 150mg/mL 1 ML 289.77 4663(E) 25-10-23 425 Mefenamic acid Oral liquid 100mg/5mL(p) 1 ML 0.56 1574(E) 31-03-23 426 Mefenamic acid Tablet 250 mg 1 Tablet 2.11 4663(E) 25-10-23 427 Mefloquine Tablet 250 mg 1 Tablet 52.16 4663(E) 25-10-23 428 Meglumine diatrizoate Injection 60%w/v 1 ML 9.47 1574(E) 31-03-23 429 Meglumine diatrizoate Injection 76%w/v 1 ML 10.20 1574(E) 31-03-23 430 Meropenem Powder for Injection 500 mg (as trihydrate) 1 Vial 723.02 1579(E) 31-03-23 431 Meropenem Powder for Injection1000mg (as trihy drate) 1 Vial 952.74 4663(E) 25-10-23 432 Mesna Injection 100mg/mL 1 ML 15.51 4663(E) 25-10-23 433 Metformin Tablet 1000mg 1 Tablet 3.49 4663(E) 25-10-23 434 Metformin Tablet 500mg 1 Tablet 2.02 4663(E) 25-10-23 435 Metformin Modified release Tablet 1000mg 1 Tablet 4.05 4663(E) 25-10-23 436 Methotrexate Tablet 10mg 1 tablet 13.29 4663(E) 25-10-23 437 Methotrexate Tablet 2.5mg 1 tablet 5.31 1574(E) 31-03-23 438 Methotrexate Tablet 5mg 1 Tablet 9.43 4663(E) 25-10-23 439 Methylergometrine Tablet 0.1 25mg 1 Tablet 8.94 4663(E) 25-10-23 440 Methylergometrine Injection 0.2mg/mL 1 ML 14.95 4663(E) 25-10-23 441 Methylprednisolone Injection 40mg/mL 1 ML 45.67 4663(E) 25-10-23 442 Metoclopramide Tablet 10mg 1 Tablet 1.35 4663(E) 25-10-23 443 Metocloprami de Injection 5mg/mL (Less than 10ML Pack) 1 ML 2.67 4663(E) 25-10-23 444 Metoclopramide Injection 5mg/mL (10 ML & More Pack) 1 ML 1.63 4663(E) 25-10-23 445 Metoclopramide Oral liquid 5mg/5mL(p) 1 ML 0.50 1577(E) 31-03-23 446 Metoprolol Tablet 25mg 1 Tab let 4.20 1574(E) 31-03-23 447 Metoprolol Tablet 50mg 1 Tablet 5.84 1574(E) 31-03-23 448 Metoprolol Modified Release Tablet 100 mg 1 Tablet 14.99 1574(E) 31-03-23 449 Metoprolol Tablet 100 mg 1 Tablet 11.13 1574(E) 31-03-23 450 Metoprolol Capsule 25mg 1 Capsule 4.14 4663(E) 25-10-23 451 Metoprolol Capsule 50mg 1 Capsule 5.82 4663(E) 25-10-23 452 Metoprolol Injection 1mg/ML 1 ML 3.40 4663(E) 25-10-23 453 Metronidazole Tablet 200mg 1 Tablet 0.82 4663(E) 25-10-23 454 Metronidazole Tablet 400mg 1 Tablet 1.52 1574(E) 31-03-23 455 Metronidazole Injection 500mg/100mL 1 ML 0.21 1574(E) 31-03-23 456 Metronidazole Oral liquid 200mg/5mL(p) 1 ML 0.52 4663(E) 25-10-23 457 Midazolam Nasal Spray 1.25mg/ actuation 1 ML 216.82 4663(E) 25-10-23 458 Midazolam Nasal Spray 0.5 mg/actuation 1 ML 79.93 1574(E) 31-03-23 459 Midazolam Injection 1mg/mL 1 ML 5.92 1574(E) 31-03-23 460 Midazolam Injection 5mg/mL 1 ML 10.88 4663(E) 25-10-23 461 Mifepristone Tablet 200mg 1 Tablet 350.92 4663(E) 25-10-23 462 Misoprostol Table t 200mcg 1 Tablet 18.97 1574(E) 31-03-23 463 Misoprostol Tablet 100mcg 1 Tablet 9.92 1574(E) 31-03-23 464 Montelukast Tablet 4 mg 1 Tablet 10.03 1574(E) 31-03-23 465 Montelukast Tablet 10 mg 1 Tablet 16.44 4663(E) 25-10-23 466 Morphine Injection 10m g/mL 1 ML 19.60 4663(E) 25-10-23 467 Morphine Injection 15mg/mL 1 ML 14.93 1574(E) 31-03-23 468 Moxifloxacin Tablet 400mg 1 Tablet 25.82 1574(E) 31-03-23 469 Mupirocin Ointment 2% 1 GM 20.29 1579(E) 31-03-23 470 Mycophenolate mofetil Tablet 250mg 1 Tablet 49.60 1574(E) 31-03-23 471 N-acetylcysteine Injection 200 mg/mL 1 ML 23.64 4663(E) 25-10-23 472 Naloxone Injection 0.4mg/mL 1 ML 92.73 1574(E) 31-03-23 473 Natamycin Drops 5% 1 ML 23.38 4663(E) 25-10-23 474 Neostigmine Injection 0.5mg/mL 1 ML 5.01 1574(E) 31-03-23 475 Neostigmine Tablet 15mg 1 Tablet 4.59 4663(E) 25-10-23 476 Nevirapine Tablet 200 mg 1 Tablet 15.80 4663(E) 25-10-23 477 Nicotine (for nicotine replacement therapy) Lozenge 2mg 1 Lozenges 7.92 4663(E) 25-10-23 478 Nicotine (for n icotine replacement therapy) Gum 2 mg 1 Gum 8.59 4663(E) 25-10-23 479 Nicotine (for nicotine replacement therapy) Gum 4 mg 1 Gum 10.64 1579(E) 31-03-23 480 Nicotine (for nicotine replacement therapy) Lozenge 4mg 1 Lozenges 9.75 1579(E) 31-03-23 481 Nifedipine Tablet 10mg 1 Tablet 1.54 4663(E) 25-10-23 482 Nifedipine Capsule10mg 1 Capsule 0.95 1577(E) 31-03-23 483 Nitrofurantoin Tablet 100 mg 1 Tablet 8.11 4663(E) 25-10-23 484 Nitrofurantoin Capsule 100 mg 1 Capsule 8.64 1577(E) 31-03-23 485 Nitrofu rantoin Oral liquid 25mg/5mL(p) 1 ML 0.89 4663(E) 25-10-23 486 Noradrenaline Injection 2mg/mL 1 ML 20.17 1574(E) 31-03-23 487 Norethisterone Tablet 5mg 1 Tablet 5.39 1574(E) 31-03-23 488 Omeprazole Capsule 20 mg 1 Capsule 2.87 1574(E) 31-03-23 489 Omep razole Tablet 20 mg 1 Tablet 4.34 4663(E) 25-10-23 490 Omeprazole Capsule 10 mg 1 Capsule 2.41 1577(E) 31-03-23 491 Omeprazole Powder for oral liquid 20mg 1 GM 1.51 1577(E) 31-03-23 492 Omeprazole Tablet 40 mg 1 Tablet 8.45 1577(E) 31-03-23 493 Ondanse tron Tablet 4 mg 1 Tablet 5.14 4663(E) 25-10-23 494 Ondansetron Oral liquid 2mg/5mL(p) 1 ML 1.26 4663(E) 25-10-23 495 Ondansetron Injection 2mg/mL 1 ML 5.96 1574(E) 31-03-23 496 Ondansetron Tablet 8 mg 1 Tablet 9.06 4663(E) 25-10-23 497 Oral rehydratio n salts As licensed 1 ML 0.15 4663(E) 25-10-23 498 Ormeloxifene (Centchroman) Tablet 30mg 1 Tablet 8.44 1579(E) 31-03-23 499 Oxaliplatin Injection 5 mg/mL in 10 mL vial 1 Vial 2233.95 4663(E) 25-10-23 500 Oxytocin Injection 5 IU/mL 1 ML 17.84 4663(E) 25-10-23 501 Oxytocin Injection 10IU/mL 1 ML 39.87 1577(E) 31-03-23 502 Paclitaxel Injection 30 mg/5 mL, injection 100 mg/16.7 ml 1 ML 215.44 1577(E) 31-03-23 503 Pantoprazole Injection 40mg 1 Vial 50.45 1574(E) 31-03-23 504 Paracetamol Tablet 650mg 1 Tablet 2.01 4663(E) 25-10-23 505 Paracetamol Oral Liquid 125 mg/5 mL (p) 1 ML 0.37 1574(E) 31-03-23 506 Paracetamol Oral Liquid 250 mg/5 mL (p) 1 ML 0.67 1574(E) 31-03-23 507 Paracetamol Oral liquid 120 mg/5 mL (p) 1 ML 0.61 4663(E) 25-10-23 508 Paracetamol Tablet 500mg 1 Tablet 0.90 4663(E) 25-10-23 509 Paracetamol Suppository 80mg 1 Suppository 6.66 1574(E) 31-03-23 510 Paracetamol Suppository 170mg 1 Suppository 7.95 4663(E) 25-10-23 511 Paracetamol Injection 150mg/mL (2ML) 1 ML 3.97 2124(E) 04-05-23 512 Paracetamol Injection150mg/mL (100 ML) 1 ML 1.60 2125(E) 04-05-23 513 Permethrin Cream 5% 1 GM 1.85 1577(E) 31-03-23 514 Permethrin Lotion 1% 1 ML 1.00 4663(E) 25-10-23 515 Permethrin Cream 1% 1 GM 1.50 1577(E) 31-03-23 516 Permethrin Lotion 5% 1 ML/GM 1.00 4663(E) 25-10-23 517 Permethrin Gel 5% 1 GM 1.31 2540(E) 08-06-23 518 Pheniramine Injection 22.75mg/mL (2ml) 1 ML 2.76 4663(E) 25-10-23 519 Pheniramine Injection 22.75mg/mL (10ml) 1 ML 2.06 1577(E) 31-03-23 520 Phenobarbitone Tablet 30mg 1 Tablet 1.31 1574(E) 31-03-23 521 Phenobarbitone Tablet 60mg 1 Tablet 1.89 1574(E) 31-03-23 522 Phenobarbitone Injection 200mg/mL 1 ML 22.14 1574(E) 31-03-23 523 Phenobarbitone Oral liquid 20mg/5mL (p) 1 ML 0.49 1574(E) 31-03-23 524 Phenytoin Tablet 300mg 1 Tablet 5.48 1574(E) 31-03-23 525 Phenytoin Injection 50mg/mL 1 ML 5.95 1574(E) 31-03-23 526 Phenytoin Modified Release Tablet 300mg 1 Tablet 6.57 1577(E) 31-03-23 527 Phenytoin Tablet 100mg 1 Tablet 1.76 1577(E) 31-03-23 528 Phenytoin Tablet 50mg 1 Tablet 0.84 1577(E) 31-03-23 529 Phenytoin Oral liquid 30mg/5 mL(p) 1 ML 0.35 4663(E) 25-10-23 530 Phenytoin Oral liquid 125mg/5mL(p) 1 ML 1.10 4663(E) 25-10-23 531 Phenytoin Capsule 300mg 1 Capsule 4.65 1577(E) 31-03-23 532 Phenytoin Caps ule 100mg 1 Capsule 1.83 4663(E) 25-10-23 533 Phytomenadione (Vitamin K1) Injection 10mg/mL 1 ML 53.09 4663(E) 25-10-23 534 Phytomenadione (Vitamin K1) Tablet 10mg 1 Tablet 14.54 1577(E) 31-03-23 535 Pilocarpine Drops 2 % 1 ML 10.83 1574(E) 31-03-23 536 Piperacillin (A) +Tazobactam(B) Powder for Injection 1000mg(A)+125mg (B) 1 Vial 99.66 1574(E) 31-03-23 537 Piperacillin (A) +Tazobactam(B) Powder for Injection 2000mg(A)+250mg (B) 1 Vial 191.55 4663(E) 25-10-23 538 Piperacillin (A) +Tazobactam(B) Powder for Injection 4000mg(A)+500mg (B) 1 Vial 399.41 4663(E) 25-10-23 539 Potassium chloride Oral liquid 500mg/5mL 1 ML 0.30 1574(E) 31-03-23 540 Potassium chloride Injection 150mg/mL 1 ML 2.40 4663(E) 25-10-23 541 Povidone iodine Solution 5% 1 ML 0.44 4663(E ) 25-10-23 542 Povidone iodine Solution 7.5% 1 ML 0.82 4663(E) 25-10-23 543 Povidone iodine Solution 10% 1 ML 0.96 1574(E) 31-03-23 544 Povidone iodine Solution 4% 1 ML 1.74 2168(E) 11-05-23 545 Pralidoxime chloride (2 -PAM) Injection 25mg/mL 1 ML 4.56 1574(E) 31-03-23 546 Prednisolone Tablet 40mg 1 Tablet 3.41 4663(E) 25-10-23 547 Prednisolone Oral liquid 5mg/5mL(p) 1 ML 0.49 1574(E) 31-03-23 548 Prednisolone Oral liquid 15mg/5mL(p) 1 ML 0.86 1574(E) 31-03-23 549 Prednisolone Tablet 10mg 1 Tablet 1.20 4663(E) 25-10-23 550 Prednisolone Tablet 5mg 1 Tablet 0.68 1574(E) 31-03-23 551 Prednisolone Tablet 20mg 1 Tablet 2.40 4663(E) 25-10-23 552 Prednisolone Drops 1% 1 ML 5.76 1574(E) 31-03-23 553 Premix Insulin 30:70 Injection (Regular:NPH) Injection 40 IU /ml 1 ml 16.99 4663(E) 25-10-23 554 Primaquine Tablet 7.5mg 1 Tablet 2.38 4663(E) 25-10-23 555 Primaquine Tablet 15mg 1 Tablet 5.14 4663(E) 25-10-23 556 Primaquine Tablet 2.5mg 1 Tablet 1.75 4663(E) 25-10-23 557 Proparacaine Eye Drops0.5% 1 ML 10.25 4663(E) 25-10-23 558 Propofol Injection 10mg/mL 1 ML 6.50 1574(E) 31-03-23 559 Propranolol Tablet 40mg 1 Tablet 3.22 4663(E) 25-10-23 560 Propranolol Tablet 10mg 1 Tablet 1.31 1574(E) 31-03-23 561 Propranolol Tablet 20mg 1 Tablet 3.20 4663(E) 25-10-23 562 Propranolol Capsule 40mg 1 Capsule 4.25 4663(E) 25-10-23 563 Propranolol Capsule 20 mg 1 Capsule 2.35 1578(E) 31-03-23 564 Propranolol Capsule 10 mg 1 Capsule 2.00 4663(E) 25-10-23 565 Protamine Sulphate Injection 10mg/mL 1 ML 9.78 4663(E) 25-10-23 566 Pyrazinamide Tablet 1000mg 1 Tablet 10.53 4663(E) 25-10-23 567 Pyrazinamide Tablet 500mg 1 Tablet 4.89 4663(E) 25-10-23 568 Pyrazinamide Tablet 750mg 1 Tablet 7.21 4663(E) 25-10-23 569 Pyrazinamide Tablet 1500mg 1 Tablet 11.81 4663(E) 25-10-23 570 Pyridoxine Tablet 100 mg 1 Tablet 5.98 4663(E) 25-10-23 571 Pyridoxine Tablet 10mg 1 Tablet 0.11 1577(E) 31-03-23 572 Quinine Tablet 300 mg 1 Tablet 5.65 1574(E) 31-03-23 573 Quinine Injection 300 mg/mL 1 ML 9.50 4663(E) 25-10-23 574 Rabies vac cine As licensed 1 Vial 378.71 1574(E) 31-03-23 575 Raltegravir Tablet 400mg 1 Tablet 147.80 4663(E) 25-10-23 576 Ramipril Tablet 2.5 mg 1 Tablet 5.21 1574(E) 31-03-23 577 Ramipril Tablet 5mg 1 Tablet 8.18 1574(E) 31-03-23 578 Ramipril Capsule 2.5mg 1 Capsule 4.66 1577(E) 31-03-23 579 Ramipril Capsule 5mg 1 Capsule 7.19 4663(E) 25-10-23 580 Ribavirin Capsule 200 mg 1 Capsule 26.49 1574(E) 31-03-23 581 Rifampicin Capsule 600mg 1 Capsule 11.36 4663(E) 25-10-23 582 Rifampicin Capsule 450mg 1 Capsule 5.67 1574(E) 31-03-23 583 Rifampicin Capsule 150mg 1 Capsule 2.29 4663(E) 25-10-23 584 Rifampicin Capsule 300mg 1 Capsule 4.61 4663(E) 25-10-23 585 Rifampicin Oral liquid 100mg/5mL(p) 1 ML 0.47 1574(E) 31-03-23 586 Risperidone Tablet 1 mg 1 Tablet 3.03 4663(E) 25-10-23 587 Risperidone Tablet 2 mg 1 Tablet 4.48 1574(E) 31-03-23 588 Risperidone Tablet 4 mg 1 Tablet 7.36 4663(E) 25-10-23 589 Risperidone Oral liquid 1mg/mL 1 ML 2.21 4663(E) 25-10-23 590 Risperidone Injection (Longacting) 25mg 1 ML 1930.30 2125(E) 04-05-23 591 Risperidone Injection (Longacting) 37.5 mg 1 ML 2649.41 2125(E) 04-05-23 592 Ritonavir Tablet 100mg 1 Tablet 29.21 4663(E) 25-10-23 593 Rituximab Injection 10mg/mL 1 ML 761.81 4663(E) 25-10-23 594 Rota virus vaccine As li censed 1 Vial 854.58 4663(E) 25-10-23 595 Salbutamol Tablet 4 mg 1 Tablet 0.21 1574(E) 31-03-23 596 Salbutamol Tablet 2 mg 1 Tablet 0.18 4663(E) 25-10-23 597 Salbutamol Oral liquid 2mg/5mL 1 ML 0.18 4663(E) 25-10-23 598 Salbutamol Inhalation 1 Dose 0.49 1574(E) 31-03-23 (MDI/DPI) 100mcg/dose 599 Salbutamol Respirator Solution (Solution for Nebulizer 5mg/mL) 1 ML 0.68 1574(E) 31-03-23 600 Salicylic acid Ointment 3 -6% (6%) 1 GM 2.02 4663(E) 25-10-23 601 Salicylicacid Ointment 3% 1 GM 2.06 1579(E) 31-03-23 602 Sevoflurane Liquid for inhalation 1 ML 31.17 4663(E) 25-10-23 603 Sodium bicarbonate Injection (as per IP) - 8.4% 1 ML 1.35 4663(E) 25-10-23 604 Sodium bicarbonate Injection (as per IP) - 7.5% 1 ML 1.01 4663(E) 25-10-23 605 Sodium Valproate Tablet 300mg 1 Tablet 4.46 1574(E) 31-03-23 606 Sodium Valproate Oral liquid 200mg/5mL(p) 1 ML 0.65 1574(E) 31-03-23 607 Sodium Valproate Tablet 200mg 1 Tablet 3.59 4663(E) 25-10-23 608 Sodium Valproate Modified Release – Tablet 500mg 1 Tablet 9.28 1574( E) 31-03-23 609 Sodium Valproate Tablet 500mg 1 Tablet 8.12 4663(E) 25-10-23 610 Sodium Valproate Modified Release – Tablet 300mg 1 Tablet 6.10 4663(E) 25-10-23 611 Sodium Valproate Injection 100mg/mL 1 ML 6.75 4663(E) 25-10-23 612 Sofosbuvir Tablet 40 0mg 1 Tablet 525.12 4663(E) 25-10-23 613 Somatostatin Powder for Injection 3mg 1 Vial 1359.00 4663(E) 25-10-23 614 Spironolactone Tablet 50mg 1 Tablet 4.37 1574(E) 31-03-23 615 Spironolactone Tablet 25mg 1 Tablet 2.19 4663(E) 25-10-23 616 Streptokinas e Injection 15,00,000IU 1 Vial 1877.33 1574(E) 31-03-23 617 Streptomycin Powder for Injection 750 mg 1 Vial 10.10 1574(E) 31-03-23 618 Streptomycin Powder for Injection 1000mg 1 Vial 10.86 1574(E) 31-03-23 619 Succinylcholine Injection 50mg/mL 1 ML 5.21 2540(E) 08-06-23 620 Sulfasalazine Tablet 500 mg 1 Tablet 4.72 1574(E) 31-03-23 621 Sumatriptan Tablet 25mg 1 Tablet 32.50 2540(E) 08-06-23 622 Sumatriptan Tablet 50mg 1 Tablet 55.68 2540(E) 08-06-23 623 Tacrolimus Capsule 0.5mg 1 Capusle 20.66 1574(E) 31-03-23 624 Tacrolimus Capsule 1mg 1 Capusle 40.62 1574(E) 31-03-23 625 Tacrolimus Capsule 2mg 1 Capusle 84.34 4663(E) 25-10-23 626 Tacrolimus Tablet 1mg 1 Tablet 39.98 4886(E) 10-11-23 627 Tacrolimus Tablet 2mg 1 Tablet 77.69 4886(E) 10-11-23 628 Tacrolimus Tablet 0.5mg 1 Tablet 20.97 4886(E) 10-11-23 629 Tamoxifen Tablet 20mg 1 Tablet 2.95 4663(E) 25-10-23 630 Tamoxifen Tablet 10mg 1 Tablet 2.21 4663(E) 25-10-23 631 Telmisartan Tablet 20mg 1 Tablet 3.88 4663(E) 25-10-23 632 Telmisartan Tablet 40mg 1 Tablet 6.76 1574(E) 31-03-23 633 Telmisartan Tablet 80mg 1 Tablet 10.40 1574(E) 31-03-23 634 Temozolomide Capsule 20 mg 1 Capsule 441.33 1574(E) 31-03-23 635 Temozolomide Capsule 250mg 1 Capsule 4304.01 1574(E) 31-03-23 636 Temozolomide Capsule 100mg 1 Capsule 1508.70 1574(E) 31-03-23 637 Temozolomide Tablet 20 mg 1 Tablet 336.65 4886(E) 10-11-23 638 Temozolomide Tablet 250 mg 1 Tablet 3758.15 4886(E) 10-11-23 639 Tenecteplase Injection 40mg/vial 1 Vial 50389.69 4663(E) 25-10-23 640 Tenecteplase Injection 30mg/vial 1 Vial 36910.02 4663(E) 25-10-23 641 Teneligliptin Tablet 20mg 1 Tablet 11.09 4663(E) 25-10-23 642 Tenofovir Alafenamide Fumarate (TAF) Tablet 25mg 1 Tablet 48.87 1574(E) 31-03-23 643 Tenofovir Disproxil Fumarate (A) + La mivudine (B) Tablet 300mg (A) + 300mg(B) 1 Tablet 45.58 4663(E) 25-10-23 644 Tenofovir Disproxil Fumarate (A) +Lamivudine (B) + Efavirenz(C) Tablet 300mg(A)+ 300mg (B) + 600mg(C) 1 Tablet 102.85 4663(E) 25-10-23 645 Tenofovir Disproxil Fumarate (TDF)* Tablet 300mg 1 Tablet 45.84 4663(E) 25-10-23 646 Terbinafine Cream 1% 1 GM 5.26 4663(E) 25-10-23 647 Tetanus toxoid As licensed (5ml) 1 Vial 25.53 1577(E) 31-03-23 648 Tetanus toxoid As licensed (0.5ml) 1 Vial (0.5ML) 12.47 4663(E) 25-10-23 649 Thalidomi de Capsule 50 mg 1 Capsule 31.16 4663(E) 25-10-23 650 Thalidomide Capsule 100mg 1 Capsule 62.01 1574(E) 31-03-23 651 Thiamine Tablet 100 mg 1 Tablet 4.46 1574(E) 31-03-23 652 Thiamine Injection 100 mg/mL 1 ML 22.59 1574(E) 31-03-23 653 Thiopentone Powd er for injection 1g 1 Vial 55.32 2540(E) 08-06-23 654 Thiopentone Powder for injection 0.5g 1 Vial 45.69 2540(E) 08-06-23 655 Timolol Drops 0.5 % 1 ML 13.40 4663(E) 25-10-23 656 Tiotropium Inhalation (MDI) 9 mcg/dose 1 MD 2.78 1574(E) 31-03-23 657 Tiotropium Inhalation (DPI) 18mcg/dose 1 DP 10.71 4663(E) 25-10-23 658 Tramadol Injection 50mg/mL (upto 2ml pack) 1 ML 11.78 1574(E) 31-03-23 659 Tramadol Capsule 50mg 1 Capsule 4.82 1577(E) 31-03-23 660 Tramadol Capsule 100mg 1 Capsule 9.04 4663(E) 25-10-23 661 Tramadol Tablet 50mg 1 Tablet 9.70 4886(E) 10-11-23 662 Tramadol Tablet 100mg 1 Tablet 24.48 4886(E) 10-11-23 663 Tranexamic acid Injection 100 mg/mL 1 ML 13.71 1574(E) 31-03-23 664 Tranexamic acid Tablet 500 mg 1 Tablet 18.54 1574(E) 31-03-23 665 Trastuzumab Injection 440mg/50mL 1 Vial 54725.21 4663(E) 25-10-23 666 Trihexyphenidyl Tablet 2mg 1 Tablet 1.37 4663(E) 25-10-23 667 Tropicamide Eye drop 1 % 1 ML 9.43 4663(E) 25-10-23 668 Valganciclovir Tablet 450 mg 1 Tablet 400.73 1574(E) 31-03-23 669 Vancomycin Powder for Injection 500 mg 1 Vial 317.64 4663(E) 25-10-23 670 Vancomycin Powder for Injection 1000mg 1 Vial 470.27 4663(E) 25-10-23 671 Vancomycin Powder for Injection 250 mg 1 Vial 251.25 1574(E) 31-03-23 672 Vancomycin Capsule 250 mg 1 Capsule 152.39 1578(E) 31-03-23 673 Vecuronium Powder for injection 10mg Each Vial 117.37 4663(E) 25-10-23 674 Vecuronium Powder for injection 4 mg Each Vial 74.40 1574(E) 31-03-23 675 Verapamil Tablet 80 mg 1 Tablet 1.59 1574(E) 31-03-23 676 Vera pamil Tablet 40mg 1 Tablet 0.86 1574(E) 31-03-23 677 Vincristine Injection 1mg/mL 1 ML 57.52 4663(E) 25-10-23 678 Vitamin A Tablet 50000IU (including Chewable Tablet) 1 Tablet 0.73 4663(E) 25-10-23 679 Vitamin A Injection 50000IU/mL 1 ML 2.26 1577(E) 31-03-23 680 Warfarin Tablet 5 mg 1 Tablet 2.40 2540(E) 08-06-23 681 Warfarin Tablet 3 mg 1 Tablet 3.18 2540(E) 08-06-23 682 Warfarin Tablet 2 mg 1 Tablet 2.72 2540(E) 08-06-23 683 Warfarin Tablet 1 mg 1 Tablet 2.46 2540(E) 08-06-23 684 Xylometazoli ne Nasal drops 0.05 % 1 ML 4.19 1574(E) 31-03-23 685 Xylometazoline Nasal drops 0.1% 1 ML 5.12 1574(E) 31-03-23 686 Zidovudine (A) +Lamivudine (B) +Nevirapine(C) Tablet 300mg(A)+150mg( B)+200mg (c) 1 Tablet 21.13 1574(E) 31-03-23 687 Zidovudine (A) +Lam ivudine(B) Tablet 300mg(A)+150mg( B) 1 Tablet 21.09 1574(E) 31-03-23 688 Zinc Sulphate Dispersible Tablet 20mg 1 Tablet 3.41 4886(E) 10-11-23 689 Zoledronic acid Powder for Injection 4mg 1 Vial 2392.05 4663(E) 25-10-23 690 Zolpidem Tablet 5mg 1 Tablet 6.21 1574(E) 31-03-23 691 Zolpidem Tablet 10mg 1 Tablet 8.51 1574(E) 31-03-23 692 Darunavir (A) +Ritonavir (B) Tablet 600mg (A) + 100mg (B) 1 Tablet 146.46 939(E) 28-02-24 693 Nicotine (for nicotine replacement therapy) Oral Dosage forms 2mg Pastille 1 Pastille 7.12 939(E) 28-02-24 694 Nicotine (for nicotine replacement therapy) Oral Dosage forms 4mg Pastille 1 Pastille 7.83 939(E) 28-02-24 695 Levonorgestrel Tablet 1.5mg 1 Tablet 75.35 939(E) 28-02-24 696 Cholecalciferol Solid oral dosage form 1000 IU Sachet/ Granuels / Powder 1 Gram 23.14 939(E) 28-02-24 697 Tenofovir Disproxil Fumarate + Lamivudine + Dolutegravir Tablet 300mg + 300mg + 50 mg 1 Tablet 114.99 939(E) 28-02-24 698 Zidovudine Tablet 300 mg 1 Tablet 13.59 938(E) 28-02-24 699 Benzath ine benzylpenicillin Powder for Injection 12 lac units 1 Vial 19.81 938(E) 28-02-24 700 Benzathine benzylpenicillin Powder for Injection 6 lac units 1 Vial 11.69 938(E) 28-02-24 701 Fentanyl Injection 50mcg/ml 1 ml 20.96 938(E) 28-02-24 702 Folic Acid Capsule 5 mg 1 Capsule 5.04 938(E) 28-02-24 703 Hyoscine butylbromide Injection 20 mg/ml 1 ml 11.24 938(E) 28-02-24 704 Omeprazole Capsule 40 mg 1 Capsule 5.67 938(E) 28-02-24 705 Desferrioxamine Powder for Injection 500mg 1 Vial 188.65 938(E) 28-02-24 706 Snake venom antiserum Lyophilized polyvalent - As Licensed 1 Vial of 10 ml 665.26 938(E) 28-02-24 707 Snake Venom Antiserum Soluble/ Liquid Polyvalent - As Licensed 1 Vial of 10 ml 428.67 938(E) 28-02-24 708 Chlorambucil Tablet 2 mg 1 Tablet 31.16 938(E) 28-02-24 709 Chlorambucil Tablet 5 mg 1 Tablet 77.21 938(E) 28-02-24 710 Melphalan Tablet 2 mg 1 Tablet 91.34 938(E) 28-02-24 711 Melphalan Tablet 5 mg 1 Tablet 86.04 938(E) 28-02-24 712 Arsenic Trioxide Injection 1mg/ml 1 ml 30.54 938(E) 28-02-24 713 5-Fluorouracil Injection 250 mg/5 ml 1 ml 2.04 938(E) 28-02-24 714 Acetylsalicylic acid Conventional / Effervescent / Dispersible / Enteric coated Tablets 325 mg 1 Tablet 0.67 938(E) 28-02-24 715 Budesonide Inhalation (MDI) 100 mcg/dose 1 Metere d Dose 1.41 938(E) 28-02-24 716 Budesonide Inhalation (MDI) 200 mcg/dose 1 Metered Dose 2.03 938(E) 28-02-24 717 Budesonide Inhalation (DPI) 200 mcg/dose 1 Dose 3.33 938(E) 28-02-24 718 Budesonide Nasal Spray 100 mcg/dose 1 Dose 0.81 938(E) 28-02-24 719 Budesonide (A)+ Formoterol (B) Inhalation (MDI) 100 mcg (A) + 6 mcg (B) 1 Metered Dose 2.12 938(E) 28-02-24 720 Budesonide (A)+ Formoterol (B) Inhalation (DPI) 100 mcg (A) + 6 mcg (B) 1 Dose 4.32 938(E) 28-02-24 721 Budesonide (A)+ Formoterol (B) Inhalation (DPI) 200 mcg (A) + 6 mcg (B) 1 Dose 5.72 938(E) 28-02-24 722 Budesonide (A)+ Formoterol (B) Inhalation (DPI) 400 mcg (A) + 6 mcg (B) 1 Dose 6.62 938(E) 28-02-24 723 Oxygen – Liquid Medical Oxygen As licensed for medical purpose Cubic Meter 17.02 1580(E) 31-03-23 724 Oxygen (in cylinder) As licensed for medical purpose Cubic Meter 28.83 1580(E) 31-03-23 725 Nitrous oxide As licensed for medical purpose Cubic Meter 285.98 4663(E) 25-10-23 726 Disposable Pen containing Insulin Glargine Inject ion 100 IU/ml 1 ML 244.14 1581(E) 31-03-23 Notes: - (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) In respect of formulation where pack w ise ceiling price is notified, for any other pack size manufactured, the manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its formulations. The formulation of Sodium Valproate includes combination of Sodium Va lproate and Valproic Acid both together corresponding to Sodium Valproate of the stated strength. (c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above, the manufacturer shall approach NPPA for specific price approva l for its formulations. (d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. (e) All the existing manufacturers of above -mentioned schedu led formulations having MRP lower than the ceiling price notified vide S.O. & date as specified in column 6 (a) & 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of their formulations, on the basi s of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revision and non -submission of information under th is sub -paragraph shall be construed as non -revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereon from the da te of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of t he Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per para 24(4) of D PCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any per son wishing to consult the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall appl y for prior price approval of such new drug to NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of sc heduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / o r import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to depo sit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of t he above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director का. आ. 1548(अ).— vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 4, 6, 10, 11, 14, 16, 17 a b @ (0.00551 %) 0.00551% (1) (2) (3) (4) (5) 6(a) 6(b) 1 5&,feukslsyhflfyd ,flM lqIiksftVªh 500 fexzk - fjVsu'ku ,fuek 1 lqIiksftVªh 21.05 4663 ( अ) 25.10.2023 2 5&,feukslsyhflfyd ,flM xksyh 400 fexzk - 1 xksyh 9.31 4663 ( अ) 25.10.2023 3 ,cdkohj ¼,½ $ ysfeoqMhu ¼ch½ xksyh 60 fexzk - ¼,½ $ 30 fexzk - ¼ch½ 1 xksyh 25.00 1573 ( अ) 31.03.2023 4 ,lhVkbylSyhflfyd ,flM bQsjoslsaV@fMLij flcy@,afVªd dksfVM xksyh 100 fexzk - 1 xksyh 0.22 1573 ( अ) 31.03.2023 5 ,lhVkbylSyhflfyd ,flM xksyh 100 fexzk - 1 xksyh 0.21 1573 ( अ) 31.03.2023 6 ,lhVkbylSyhflfyd ,flM xksyh 150 fexzk - 1 xksyh 0.50 1573 ( अ) 31.03.2023 7 ,lhVkbylSyhflfyd ,flM xksyh 350 fe xzk- 1 xksyh 0.38 1573 ( अ) 31.03.2023 8 ,lhVkbylSyhflfyd ,flM xksyh 75 fexzk - 1 xksyh 0.38 1573 ( अ) 31.03.2023 9 vkWy&Vªkal jsVhukWbd ,flM dSIlwy 10 fexzk - 1 dSIlwy 101.85 1573 ( अ) 31.03.2023 10 ,EQksVsfjflu ch ¼fyfiM½ batSD'ku ds fy, ikmMj 50 fexzk- izfr iSd 3990.62 1573 ( अ) 31.03.2023 11 ,EQksVsfjflu ch ¼fyikslksey½ batSD'ku ds fy, ikmMj 50 fexzk- izfr iSd 9295.41 4663 ( अ) 25.10.2023 12 ,Eihflfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 26.56 1573 ( अ) 31.03.2023 13 ,aVh&Mh bEequksXykscqfyu batSD'ku 300 ,elhth izfr iSd 2657.47 1573 ( अ) 31.03.2023 14 ,aVh&Mh bEequksXykscqfyu batSD'ku 150 ,elhth izfr ok;y 2071.40 1573 ( अ) 31.03.2023 15 ,aVh&jscht bEequksXykscqfyu batSD'ku 150 vkbZ;w@fefy - 1 fefy- 3454.06 4663 ( अ) 25.10.2023 16 ,aVh&jscht bEequksXykscqf yu batSD'ku 300 vkbZ;w@fefy - 1 fefy- 121.77 1573 ( अ) 31.03.2023 17 ,aVh&VsVul bEequksXykscqfyu 250 vkbZ;w izfr iSd 1383.57 1573 ( अ) 31.03.2023 18 vVsZlqusV ¼,½ $ lYQkMkWDlhu & fifjesFkkekbu ¼ch½ xksyh 100 fexzk - ¼,½ $ 1 xksyh ¼750 fexzk - $ 37-5 fexzk-½ ¼ch½ dksEch iSd 36.72 4663 ( अ) 25.10.2023 19 vVsZlqusV ¼,½ $ lYQkMkWDlhu & fifjesFkkekbu ¼ch½ xksyh 150 fexzk - ¼,½ $ 2 xksyh ¼500 fexzk - $ 25 fexzk -½ ¼ch½ dksEch iSd 49.85 4663 ( अ) 25.10.2023 20 vVsZlqusV ¼,½ $ lYQkMkWDlhu & fifjesFkkekbu ¼ch½ xksyh 200 fexzk- ¼,½ $ 2 xksyh ¼750 fexzk - $ 37-5 fexzk-½ ¼ch½ dksEch iSd 45.45 1573 ( अ) 31.03.2023 21 vVsZlqusV ¼,½ $ lYQkMkWDlhu & fifjesFkkekbu ¼ch½ xksyh 25 fexzk - ¼,½ $ 1 xksyh ¼250 fexzk - $ 12-5 fexzk-½ ¼ch½ dksEch iSd 24.48 4663 ( अ) 25.10.2023 22 chlhth oSD lhu izfr Mkst 11.12 1573 ( अ) 31.03.2023 23 csutks,y isjkDlkbM Øhe 2-5% 1 xzke 2.90 1573 ( अ) 31.03.2023 24 csutkby isfuflfyu batSD'ku ds fy, ikmMj 10 yk[k ;wfuV izfr iSd 9.71 4663 ( अ) 25.10.2023 25 chVkesFklksu tSy 0-05% 1 xzke 0.66 1573 ( अ) 31.03.2023 26 chVkesFklksu yks'ku 0-1% 1 fefy- 1.02 1573 ( अ) 31.03.2023 27 chVkesFklksu yks'ku 0-5% 1 fefy- 0.66 1573 ( अ) 31.03.2023 28 cqMslksukbM usty Lizs 50 ,elhth@Mkst 1 Mkst 1.27 4663 ( अ) 25.10.2023 29 cqMslksukbM bugsys'ku ¼MhihvkbZ½ 100 ,elhth@Mkst 2.49 4663 ( अ) 25.10.2023 30 cqMslksukbM ¼,½ $ QkseksZVsjksy ¼ch½ bugsys'ku ¼,eMhvkbZ ½ 200 ,elhth ¼,½ $ 6 ,elhth ¼ch½ 3.33 1573 ( अ) 31.03.2023 31 cqMslksukbM ¼,½ $ QkseksZVsjksy ¼ch½ bugsys'kku ¼,eMhvkbZ ½ 400 ,elhth ¼,½ $ 6 ,elhth ¼ch½ 3.80 1573 ( अ) 31.03.2023 32 dSfY'k;e dkWcksZusV Xksyh 500 fexzk - 1 xksyh 2.15 1573 ( अ) 31.03.2023 33 dSfY'k;e XyqdksusV batSD'ku 100 fexzk -@fefy- 1 fefy- 0.68 1573 ( अ) 31.03.2023 34 lsQkMªksDlhy dSIlwy 500 fexzk - 1 dSIlwy 8.90 1573 ( अ) 31.03.2023 35 lsQktksfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 30.56 1573 ( अ) 31.03.2023 36 lsQktksfyu batSD'ku ds fy, ikmMj 500 fexzk- izfr iSd 19.37 1573 ( अ) 31.03.2023 37 lsfQDlhe dSIlwy 400 fexzk - 1 dSIlwy 36.41 4663 ( अ) 25.10.2023 38 lsfVªftu dSIlwy 10 fexzk - 1 dSIlwy 2.96 1573 ( अ) 31.03.2023 39 DyksjgsDlkMhu lksyq'ku 5 % ¼da'kuVªsV QkWj fMyq'ku½ 1 fefy- 0.19 1573 ( अ) 31.03.2023 40 DyksDlkflfyu dSIlwy 250 fexzk - 1 dSIlwy 1.41 1573 ( अ) 31.03.2023 41 DyksDlkflfyu dSIlwy 500 fexzk - 1 dSIlwy 2.38 4663 ( अ) 25.10.2023 42 DyksDlkflfyu xksyh 250 fexzk - 1 xksyh 2.15 1573 ( अ) 31.03.2023 43 DyksDlkflfyu batSD'ku ds fy, ikmMj 250 fexzk- izfr iSd 5.53 4663 ( अ) 25.10.2023 44 dksxqys'ku QSDVj IX batSD'ku ds fy, ikmMj 600 vkbZ;w izfr iSd 15339.76 1573 ( अ) 31.03.2023 45 dkssxqys'ku QSDVj VIII batSD'ku ds fy, ikmMj 250 vkbZ;w izfr iSd 4650.15 1573 ( अ) 31.03.2023 46 dksxqys'ku QSDVj VIII batSD'ku ds fy, ikmMj 500 vkbZ;w izfr iSd 11411.13 1573 ( अ) 31.03.2023 47 lkbDyksLiksfju batSD'ku 50 fexzk -@fefy- 1 fefy- 335.80 1573 ( अ) 31.03.2023 48 MkSuk:fclhu I.V. batSD'ku ds fy, ikmMj 20 fexzk- ¼5 fexzk-@fefy-½ izfr iSd 302.76 1573 ( अ) 31.03.2023 49 MsDlkVªku&40 batSD'ku 10 % 1 fefy- 1.05 1573 ( अ) 31.03.2023 50 Mk;tsike vksjy fyD;wbZM 2 fexzk -@5 fefy- 1 fefy- 3.40 4663 ( अ) 25.10.2023 51 fMDyksQsud dSIlwy 50 fexzk - 1 dSIlwy 0.76 1573 ( अ) 31.03.2023 52 fMlkbDyksekbu vksjy lksyq'ku 10 fexzk -@5 fefy- 1 fefy- 0.20 1573 ( अ) 31.03.2023 53 fMlkbDyksekbu xksyh 10 fexzk - 1 xksyh 0.13 1573 ( अ) 31.03.2023 54 MkbuksizksLVksu xksyh 0-5 fexzk- 1 xksyh 62.31 4663 ( अ) 25.10.2023 55 MkbQFksfj;k ,VhaVksDlhu 10000 vkbZ;w izfr iSd 1631.70 4663 ( अ) 25.10.2023 56 MhihVh oSDlhu izfr 0-5 fefy- 17.64 4663 ( अ) 25.10.2023 57 bQkohjsat dSIlwy 600 fexzk - 1 dSIlwy 78.09 1573 ( अ) 31.03.202 3 58 bFkkbZy ,Ydksgy ¼MhuspjM½ lksY;q'ku 70 izfr 'kr 1 fefy- 0.53 4663 ( अ) 25.10.2023 59 Qsjl lkYV ¼,½ $ Qksfyd ,flM ¼ch½ Xkksyh 100 fexzk - byhesuVy vk;ju ¼,½ $ 500 ,elhth ¼ch½ 1 xksyh 0.28 1573 ( अ) 31.03.2023 60 ¶ywdksuktksy vksjy fyD;wbZM 50 fexzk -@5 fefy- 1 fefy- 3.25 1573 ( अ) 31.03.2023 61 xkMkscsusV batSD'ku 529 fexzk -@fefy- 1 fefy- 135.69 4663 ( अ) 25.10.2023 62 Xywdkst batSD'ku 50 % 1 fefy- 0.61 4663 ( अ) 25.10.2023 63 Xywdkst batSD'ku 5 % 1000 fefy - Xykl 79.95 1573 ( अ) 31.03.2023 64 Xywdkst batSD'ku 5 % 1000 fefy - ukWu Xykl 64.55 4663 ( अ) 25.10.2023 65 Xywdkst batSD'ku 5 % 100 fefy - Xykl 22.45 4663 ( अ) 25.10.2023 66 Xywdkst batSD'ku 5 % 100 fefy - ukWu Xykl 20.32 4663 ( अ) 25.10.2023 67 Xywdkst batSD'ku 5 % 250 fefy - Xykl 31.01 1573 ( अ) 31.03.2023 68 Xywdkst batSD'ku 5 % 250 fefy - ukWu Xykl 28.02 4663 ( अ) 25.10.2023 69 Xywdkst batSD'ku 5 % 500 fefy - Xykl 44.02 4663 ( अ) 25.10.2023 70 Xywdkst batSD'ku 5 % 500 fefy - ukWu Xykl 37.98 4663 ( अ) 25.10.2023 71 Xywdkst batSD'ku 10 % izfr iSd ¼1000 fefy -½ 32.16 4663 ( अ) 25.10.2023 72 Xywdkst batSD'ku 10 % izfr iSd ¼500 fefy -½ 34.97 1573 ( अ) 31.03.2023 73 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5 % ¼,½ $ 0-9% ¼ch½ 1000 fefy - Xykl 80.48 1573 ( अ) 31.03.2023 74 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5 % ¼,½ $ 0-9% ¼ch½ 1000 fefy - ukWu Xykl 65.03 1573 ( अ) 31.03.2023 75 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5 % ¼,½ $ 0-9% ¼ch½ 100 fefy - Xykl 22.50 1573 ( अ) 31.03.2023 76 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5 % ¼,½ $ 0-9% ¼ch½ 100 fefy - ukWu Xykl 20.34 4663 ( अ) 25.10.2023 77 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5 % ¼,½ $ 0-9% ¼ch½ 250 fefy - Xykl 31.14 4663 ( अ) 25.10.2023 78 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5 % ¼,½ $ 0-9%¼ch½ 250 fefy - ukWu Xykl 28.12 1573 ( अ) 31.03.2023 79 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5% ¼,½ $ 0 -9% ¼ch½ 500 fefy - Xykl 44.23 1573 ( अ) 31.03.2023 80 Xywdkst ¼,½ $ lksfM;e DyksjkbM ¼ch½ batSD'ku 5 % ¼,½ $ 0-9% ¼ch½ 500 fefy - ukWu Xykl 38.21 1573 ( अ) 31.03.2023 81 XywVkjkyMsgkbM lksyq'ku 2 % 1 fefy- 0.08 4663 ( अ) 25.10.2023 82 xzhlksQqyfou xksyh 125 fexzk - 1 xksyh 1.02 1573 ( अ) 31.03.2023 83 xzhlksQqyfou xksyh 375 fexzk - 1 xksyh 5.35 4663 ( अ) 25.10.2023 84 gseksMk;ylhl ¶ywM ykblsal ds vuqlkj 1 fefy- 0.04 1573 ( अ) 31.03.2023 85 g~;qeu ukWeZy bEequksXykscqfyu lksyq'ku QkWj buQ~;wtu 5 izfr'kr 1 fefy- 192.07 1573 ( अ) 31.03.2023 86 g~;qeu ukWeZy bEequksXykscqfyu lksyq'ku QkWj buQ~;wtu 10 izfr'kr 1 fefy- 260.04 1573 ( अ) 31.03.2023 87 g~;qeu ukWeZy bEequksXykscqfyu lksyq'ku QkWj buQ~;wtu 16.5 izfr'kr 1 fefy- 494.52 1573 ( अ) 31.03.2023 88 gkbMªksDyksjksFkkbtkbM xksyh 50 fexzk - 1 xksyh 0.10 1573 ( अ) 31.03.2023 89 gkbMªkstu isjksDlkbM lksyq'ku 6 % 1 fefy- 0.04 1573 ( अ) 31.03.2023 91 vkbZcqizksQqu dSIlwy 400 fexzk - 1 dSIlwy 1.31 1573 ( अ) 31.03.2023 vkbZcqizksQqu dSIlwy 200 fexzk - 1 lkWQ~V tsysVkbu dSIlwy 3.33 1573 ( अ) 31.03.2023 93 besfVuhc dSIlwy 400 fexzk - 1 dSIlwy 318.01 4663 ( अ) 25.10.2023 94 vkbZizkVªksfi;e bugsys'ku ¼,eMhvkbZ@MhihvkbZ½ 20 ,elhth@Mkst 1 Mkst 0.76 1573 ( अ) 31.03.2023 vkbZizkVªksfi;e jslfijsVkWjh lksyq'ku QkWj ;wt bu uscqykbtj 250 ,elhth@fefy - 1 fefy- 3.15 1573 ( अ) 31.03.2023 96 dSVkekbu batSD'ku 10 fexzk -@fefy- 1 fefy- 13.19 4663 ( अ) 25.10.2023 97 ysoksuksxsZLVªsy xksyh 0-75 fexzk- 1 xksyh 28.65 4663 ( अ) 25.10.2023 98 ysoksFkkbjksDlhu xksyh 37 .50 ,elhth 1 xksyh 1.47 4663 ( अ) 25.10.2023 99 fyXuksdsu ¼,½ $ ,Mªsukykbu ¼ch½ batSD'ku 1 %¼,½ $ 1%200000¼5 ,elhth@fefy -½ ¼ch½ 1 fefy- 0.56 1573 ( अ) 31.03.2023 100 yksfiukohj ¼,½ $fjVksukohj ¼ch½ xksyh 100 fexzk - ¼,½ $ 25 fexzk- ¼ch½ 1 xksyh 29.28 4663 ( अ) 25.10.2023 101 fetyl :csyk oSDlhu izfr iSd ¼0 -5 fefy-½ 110.07 4663 ( अ) 25.10.2023 102 fetyl oSDlhu oSDlhu izfr iSd ¼0 -5 fefy-½ 63.47 1573 ( अ) 31.03.2023 103 esFkksVªsDlsV batSD'ku 50 fexzk -@fefy- 1 fefy- 49.86 1573 ( अ) 31.03.2023 106 feMktksye xksyh 7-5 fexzk- 1 xksyh 27.94 1573 ( अ) 31.03.2023 107 eksQhZu ,lvkj xksyh 30 fexzk - 1 xksyh 6.78 1573 ( अ) 31.03.2023 108 eksQhZu xksyh 10 fexzk - 1 xksyh 6.63 4663 ( अ) 25.10.2023 109 ,u&,flVkb yflLVsu lpsV 200 fexzk - 1 xzke 11.20 1573 ( अ) 31.03.2023 110 usohjkikbu vksjy fyD;wbZM 50 fexzk -@5 fefy- 1 fefy- 1.04 1573 ( अ) 31.03.2023 111 vksesizktksy xksyh 10 fexzk - 1 xksyh 5.52 4663 ( अ) 25.10.2023 1 fefy- 127.67 1573 ( अ) 31.03.2023 113 vksjy fjgkbMªs'ku lkYVl ykblsal ds :i esa 1 xzke 1.11 1573 ( अ) 31.03.2023 114 vksDlkyhIykVhu batSD'ku 100 fexzk -¼ykblsal ds :i esa½ izfr iSd 5563.91 4663 ( अ) 25.10.2023 115 ikjk&,feukslkfyflfyd ,flM xzsU;wyl ¼ykblsal ds :i esa½ 1 xzke 3.54 1573 ( अ) 31.03.2023 116 isjkflVkeksy batSD'ku 150 fexzk -@fefy- izfr iSd ¼0 -5 fefy-½ 3.82 1573 ( अ) 31.03.2023 117 isjkflVkeksy batSD'ku 150 fexzk -@fefy- izfr iSd ¼1 fefy-½ 5.22 1573 ( अ) 31.03.2023 118 isjkflVkeksy batSD'ku 150 fexzk -@fefy- izfr iSd ¼3 fefy-½ 10.84 1573 ( अ) 31.03.2023 119 isjkflVkeksy batSD'ku 150 fexzk -@fefy- izfr iSd ¼4 fefy-½ 13.65 4663 ( अ) 25.10.2023 120 isjkflVkeksy batSD'ku 150 fexzk -@fefy- izfr iSd ¼5 fefy-½ 16.46 4663 ( अ) 25.10.2023 121 isjkflVkeksy batSD'ku 150 fexzk -@fefy- izfr iSd ¼7 fefy-½ 22.07 4663 ( अ) 25.10.2023 122 isfuflykekbu dSIlwy 250 fexzk - 1 dSIlwy 18.50 1573 ( अ) 31.03.2023 123 QsuhysQjhu MªksIl 10 % 1 fefy- 10.06 4663 ( अ) 25.10.2023 124 QsuhysQjhu MªksIl 5 % 1 fefy- 4.64 1573 ( अ) 31.03.2023 125 QsuhVksbu bZvkj dSIlwy 300 fexzk - 1 dSIlwy 4.74 1573 ( अ) 31.03.2023 126 QsuhVksbu batSD'ku 25 fexzk -@fefy- 1 fefy- 3.13 4663 ( अ) 25.10.2023 127 fiyksdkjfiu MªksIl 4 % 1 fefy- 14.54 1573 ( अ) 31.03.2023 128 iksVsf'k;e ijesaxusV fØLVy QkWj VkWfidy lksyq'ku 1 xzke 0.55 4663 ( अ) 25.10.2023 129 ikWfoMu vk;ksMhu स्क्रब 7-5% 1 fefy- 2.00 4663 ( अ) 25.10.2023 130 ikWfoMu vk;ksMhu vksbuVesaV 10 % 1 xzke 6.48 1573 ( अ) 31.03.2023 131 izkftD;wuVsy xksyh 600 fexzk 1 xksyh 43.25 4663 ( अ) 25.10.2023 132 izsMfulksyksu batSD'ku 20 fexzk-@2 fefy - 1 fefy- 4.46 1573 ( अ) 31.03.2023 133 ikbjkftukekbM vksjy fyD;wbZM 250 fexzk -@5 fefy- 1 fefy- 0.76 1573 ( अ) 31.03.2023 134 fjQefiflu xksyh 150 fexzk - 1 xksyh 2.01 4663 ( अ) 25.10.2023 135 fjQefiflu xksyh 300 fexzk - 1 xksyh 3.66 4663 ( अ) 25.10.2023 136 fjaxj ySDVsV batSD'ku 1000 fefy - izfr iSd 99.32 4663 ( अ) 25.10.2023 137 fjaxj ySDVsV batSD'ku 100 fefy - izfr iSd 26.00 1573 ( अ) 31.03.2023 138 fjaxj ySDVsV batSD'ku 250 fefy - izfr iSd 44.33 1573 ( अ) 31.03.2023 139 fjaxj ySDVsV batSD'ku 500 fefy - izfr iSd 56.50 4663 ( अ) 25.10.2023 140 fjVksukohj dSIlwy 100 fexzk - 1 dSIlwy 35.14 4663 ( अ) 25.10.2023 141 lsycqVkeksy dSIlwy 4 fexzk - 1 dSIlwy 0.74 1573 ( अ) 31.03.2023 142 flYoj lYQkMkbftu Øhe 1 % 1 xzke 0.63 4663 ( अ) 25.10.2023 143 lksfM;e D yksjkbM batSD'ku 0 -9% 1000 fefy - Xykl 73.88 4663 ( अ) 25.10.2023 144 lksfM;e DyksjkbM batSD'ku 0 -9% 1000 fefy - ukWu Xykl 58.27 4663 ( अ) 25.10.2023 145 lksfM;e DyksjkbM batSD'ku 0 -9% 100 fefy - Xykl 21.84 1573 ( अ) 31.03.2023 146 lksfM;e DyksjkbM batSD'ku 0-9% 100 fefy - ukWu Xykl 19.68 4663 ( अ) 25.10.2023 147 lksfM;e DyksjkbM batSD'ku 0 -9% 250 fefy - Xykl 29.47 4663 ( अ) 25.10.2023 148 lksfM;e DyksjkbM batSD'ku 0 -9% 250 fefy - ukWu Xykl 26.45 4663 ( अ) 25.10.2023 149 lksfM;e DyksjkbM batSD'ku 0 -9% 500 fefy - Xykl 40.97 4663 ( अ) 25.10.2023 150 lksfM;e DyksjkbM batSD'ku 0 -9% 500 fefy - ukWu Xykl 34.87 4663 ( अ) 25.10.2023 151 lksfM;e ukbZVªsV batSD'ku 30 fexzk -@fefy- 1 fefy- 32.35 4663 ( अ) 25.10.2023 152 lksfM;e ukbVªksi:lkbM batSD'ku 10 fexzk -@fefy- 1 fefy- 32.15 4663 ( अ) 25.10.2023 153 LVªsIVksfdukl batSD'ku 7]50]000 vkbZ;w izfr iSd 1567.42 4663 ( अ) 25.10.2023 ljQsDVkaV lLisa'ku QkWj buVªkVªkpsy buLVkbys'ku ¼ykblsal ds :i esa½ izfr iSd esa izfr fefy - QksLQksfyfiM~ l 83.27 1573 ( अ) 31.03.2023 पैर्क 23.33 1573 ( अ) 31.03.2023 ममली. पैर्क 219.25 1573 ( अ) 31.03.2023 0.5 ममली. 20.00 1573 ( अ) 31.03.2023 158 VsekstksyksekbM xksyh 100 fexzk - 1 xksyh 1925.59 4663 ( अ) 25.10.2023 159 fVeksyksy MªksIl 0-25% 1 fefy- 6.44 4663 ( अ) 25.10.2023 160 VªkekMksy batSD'ku 50 fexzk -@fefy- ¼20 fefy- iSd½ 1 fefy- 1.55 4663 ( अ) 25.10.2023 161 osjkikfey batSD'ku 2 -5 fexzk-@fefy- 1 fefy- 1.46 4663 ( अ) 25.10.2023 162 fouOykLVhu batSD'ku 1 fexzk -@fefy- 1 fefy- 25.54 1573 ( अ) 31.03.2023 163 foVkfeu , dSIlwy 50000 vkbZ;w 1 dSIlwy 0.68 1573 ( अ) 31.03.2023 164 okVj QkWj batSD'ku batSD'ku izfr iSd ¼10 fefy-½ 2.89 1573 ( अ) 31.03 .2023 165 okVj QkWj batSD'ku batSD'ku izfr iSd ¼5 fefy-½ 2.79 1573 ( अ) 31.03.2023 166 okVj QkWj batSD'ku batSD'ku izfr iSd ¼500 fefy -½ 57.40 4663 ( अ) 25.10.2023 167 okVj QkWj batSD'ku batSD'ku izfr iSd ¼1000 fefy -½ 100.74 1573 ( अ) 31.03.2023 168 ftMksoqMkbu dSIlwy 300 fexzk - 1 dSIlwy 2.57 4663 ( अ) 25.10.2023 169 tksyfiMse dSIlwy 5 fexzk - 1 dSIlwy 9.15 4663 ( अ) 25.10.2023 - ( 0.00551 % ) 11(3) (5) a b 0.00551 (5) V (4) (1) u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March , 2024 S.O. 1548 (E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and Strength Unit Ceilin g price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O. No. & Date (1) (2) (3) (4) (5) 6(a) 6(b) 1 5-aminosalicylic Acid Suppository 500 mg Retention Enema 1 Suppository 21.05 4663(E) 25.10.2023 2 5-aminosalicylic Acid Tablet 400 mg 1 Tablet 9.31 4663(E) 25.10.2023 3 Abacavir (A) + Lamivudine (B) Tablet 60 mg(A) + 30 mg(B) 1 Tablet 25.00 1573(E) 31.03.2023 4 Acetylsalicylic acid Effervescent/ Dispersible/ Enteric coated Tablet 100 mg 1 Tablet 0.22 1573(E) 31.03.2023 5 Acetylsalicylic acid Tablet 100 mg 1 Tablet 0.21 1573(E) 31.03.2023 6 Acetylsalicylic acid Tablet 150 mg 1 Tablet 0.50 1573(E) 31.03.2023 7 Acetylsalicylic acid Tablet 350mg 1 Tablet 0.38 1573(E) 31.03.2023 8 Acetylsalicylic acid Tablet 75 mg 1 Tablet 0.38 1573(E) 31.03.202 3 9 All-trans Retinoic Acid Capsule 10 mg 1 Capsule 101.85 1573(E) 31.03.2023 10 Amphotericin B (Lipid) Powder for Injection 50 mg Each Pack 3990.62 1573(E) 31.03.2023 11 Amphotericin B (Liposomal) Powder for Injection 50 mg Each Pack 9295.41 4663(E) 25.10.2023 12 Ampicillin Powder for Injection 1 gm Each Pack 26.56 1573(E) 31.03.2023 13 Anti-D immunoglobulin Injection 300mcg Each Pack 2657.47 1573(E) 31.03.2023 14 Anti-D Immunoglobulin Injection 150mcg Each Vial 2071.40 1573(E) 31.03.2023 15 Anti-rabies immunoglobulin Injection 150 IU/ml 1 ml 3454.06 4663(E) 25.10.2023 16 Anti-rabies immunoglobulin Injection 300 IU/ml 1 ml 121.77 1573(E) 31.03.2023 17 Anti-tetanus immunoglobulin 250IU Each Pack 1383.57 1573(E) 31.03.2023 18 Artesunate (A) + Sulphadoxine - Pyrimethamine (B) Tablet 100 mg(A) + 1 Tablet (750 mg+ 37.5 mg) (B) Combi pack 36.72 4663(E) 25.10.2023 19 Artesunate (A) + Sulphadoxine - Pyrimethamine (B) Tablet 150 mg(A) + 2 Tablet (500 mg+ 25 mg) (B) Combi pack 49.85 4663(E) 25.10.2 023 20 Artesunate (A) + Sulphadoxine - Pyrimethamine (B) Tablet 200 mg(A) + 2 Tablet (750 mg+ 37.5 mg) (B) Combi pack 45.45 1573(E) 31.03.2023 21 Artesunate (A) + Sulphadoxine - Pyrimethamine (B) Tablet 25 mg(A) + 1 Tablet (250 mg+ 12.5 mg) (B) Combi p ack 24.48 4663(E) 25.10.2023 22 BCG vaccine Each Dose 11.12 1573(E) 31.03.2023 23 Benzoyl Peroxide Cream 2.5% 1 gm 2.90 1573(E) 31.03.2023 Sl. No. Medicines Dosage form and Strength Unit Ceilin g price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O. No. & Date (1) (2) (3) (4) (5) 6(a) 6(b) 24 Benzyl penicillin Powder for Injection 10 Lac Units Each Pack 9.71 4663(E) 25.10.2023 25 Betamethasone Gel 0.05% 1 gm 0.66 1573(E) 31.03.2023 26 Betamethasone Lotion 0.1% 1 ml 1.02 1573(E) 31.03.2023 27 Betamethasone Lotion 0.5% 1 ml 0.66 1573(E) 31.03.2023 28 Budesonide Nasal Spray 50 mcg/dose 1 Dose 1.27 4663(E) 25.10.2023 29 Budesonide Inhalation (DPI ) 100 mcg/dose Per Dose 2.49 4663(E) 25.10.2023 30 Budesonide (A)+ Formoterol (B) Inhalation (MDI) 200 mcg (A) + 6 mcg (B) Per Metered Dose 3.33 1573(E) 31.03.2023 31 Budesonide (A)+ Formoterol (B) Inhalation (MDI) 400 mcg (A) + 6 mcg (B) Per Metered Dose 3.80 1573(E) 31.03.2023 32 Calcium Carbonate Tablet 500mg 1 Tablet 2.15 1573(E) 31.03.2023 33 Calcium gluconate Injection 100 mg/ml 1 ml 0.68 1573(E) 31.03.2023 34 Cefadroxil Capsule 500 mg 1 Capsule 8.90 1573(E) 31.03.2023 35 Cefazolin Powder for Injection 1 gm Each Pack 30.56 1573(E) 31.03.2023 36 Cefazolin Powder for Injection 500 mg Each Pack 19.37 1573(E) 31.03.2023 37 Cefixime Capsule 400 mg 1 Capsule 36.41 4663(E) 25.10.2023 38 Cetirizine Capsule 10 mg 1 Capsule 2.96 1573(E) 31.03.2023 39 Chlorhexidine Solution 5% (Concentrate for dilution) 1 ml 0.19 1573(E) 31.03.2023 40 Cloxacillin Capsule 250mg 1 Capsule 1.41 1573(E) 31.03.2023 41 Cloxacillin Capsule 500mg 1 Capsule 2.38 4663(E) 25.10.2023 42 Cloxacillin Tablet 250mg 1 Tablet 2.15 1573(E) 31.03.2023 43 Cloxacillin Powder for Injection250mg Each Pack 5.53 4663(E) 25.10.2023 44 Coagulation factor IX Powder for Injection 600 IU Each Pack 15339.76 1573(E) 31.03.2023 45 Coagulation factor VIII Powder for Injection 250 IU Each pack 4650.1 5 1573(E) 31.03.2023 46 Coagulation factor VIII Powder for Injection 500 IU Each Pack 11411.13 1573(E) 31.03.2023 47 Cyclosporine Injection 50 mg/ml 1 ml 335.80 1573(E) 31.03.2023 48 Daunarubicin Powder for I.V. Injection 20 mg (5 mg/ml) Each pack 302.76 1573(E) 31.03.2023 49 Dextran -40 Injection 10% 1 ml 1.05 1573(E) 31.03.2023 50 Diazepam Oral Liquid 2 mg/5ml 1 ml 3.40 4663(E) 25.10.2023 51 Diclofenac Capsule 50 mg 1 Capsule 0.76 1573(E) 31.03.2023 52 Dicyclomine Oral Solution 10mg/5ml 1 ml 0.20 1573(E) 31.03.2023 53 Dicyclomine Tablet 10mg 1 Tablet 0.13 1573(E) 31.03.2023 Sl. No. Medicines Dosage form and Strength Unit Ceilin g price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O. No. & Date (1) (2) (3) (4) (5) 6(a) 6(b) 54 Dinoprostone Tablet 0.5mg 1 Tablet 62.31 4663(E) 25.10.2023 55 Diphtheria antitoxin 10000 IU Each Pack 1631.70 4663(E) 25.10.2023 56 DPT vaccine Per 0.5 ml 17.64 4663(E) 25.10.2023 57 Efavirenz Capsule 600 mg 1 Capsule 78.09 1573(E) 31.03.2023 58 Ethyl Alcohol (Denatured) Solution 70% 1 ml 0.53 4663(E) 25.10.2023 59 Ferrous Salt (A) + Folic Acid (B) Tablet 100mg elemental iron (A) + 500mcg (B) 1 Tablet 0.28 1573(E) 31.03.2023 60 Fluconazole Oral Liquid 50mg/5ml 1 ml 3.25 1573(E) 31.03.2023 61 Gadobenate Injection 529 mg/ml 1 ml 135.69 4663(E) 25.10.2023 62 Glucose Injection 50% 1 ml 0.61 4663(E) 25.10.2023 63 Glucose Injection 5% 1000ml Glass 79.95 1573(E) 31.03.202 3 64 Glucose Injection 5% 1000ml Non - Glass 64.55 4663(E) 25.10.2023 65 Glucose Injection 5% 100ml Glass 22.45 4663(E) 25.10.2023 66 Glucose Injection 5% 100ml Non - Glass 20.32 4663(E) 25.10.2023 67 Glucose Injection 5% 250ml Glass 31.01 1573(E) 31.03.20 23 68 Glucose Injection 5% 250ml Non - Glass 28.02 4663(E) 25.10.2023 69 Glucose Injection 5% 500ml Glass 44.02 4663(E) 25.10.2023 70 Glucose Injection 5% 500ml Non - Glass 37.98 4663(E) 25.10.2023 71 Glucose Injection 10% Each Pack (1000 ml) 32.16 4663(E) 25.10.2023 72 Glucose Injection 10% Each Pack (500 ml) 34.97 1573(E) 31.03.2023 73 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 1000ml Glass 80.48 1573(E) 31.03.2023 74 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 1000 ml Non - Glass 65.03 1573(E) 31.03.2023 75 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 100ml Glass 22.50 1573(E) 31.03.2023 76 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 100ml Non - Glass 20.34 4663(E) 25.10.2023 77 Gluc ose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 250ml Glass 31.14 4663(E) 25.10.2023 78 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 250ml Non - Glass 28.12 1573(E) 31.03.2023 79 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 500ml Glass 44.23 1573(E) 31.03.2023 80 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 500ml Non - Glass 38.21 1573(E) 31.03.2023 81 Glutaraldehyde Solution 2% 1 ml 0.08 4663(E) 25.10.2023 82 Griseofulvin Tablet 125mg 1 Tablet 1.02 1573(E) 31.03.2023 83 Griseofulvin Tablet 375 mg 1 Tablet 5.35 4663(E) 25.10.2023 84 Haemodialysis fluid As license 1 ml 0.04 1573(E) 31.03.2023 85 Human Normal Solution for 1 ml 192.07 1573(E) 31.03.2023 Sl. No. Medicines Dosage form and Strength Unit Ceilin g price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O. No. & Date (1) (2) (3) (4) (5) 6(a) 6(b) Immunoglobulin infusion 5% 86 Human Normal Immunoglobulin Solution for infusion 10% 1 ml 260.04 1573(E) 31.03.2023 87 Human Normal Immunoglobulin Solution for infusion 16.5% 1 ml 494.52 1573(E) 31.03.2023 88 Hydrochlorothiazide Tablet 50 mg 1 Tablet 0.10 1573(E) 31.03.2023 89 Hydrogen peroxide Solution 6% 1 ml 0.04 1573(E) 31.03.2023 90 Hydroxocobalamin Injection 1 mg/ml 1 ML 12.31 1573(E) 31.03.2023 91 Ibuprofen Capsule 400 mg 1 Capsule 1.31 1573(E) 31.03.2023 92 Ibuprofen Capsule 200 mg 1 soft gelatin capsule 3.33 1573(E) 31.03.2023 93 Imatinib Capsule 400 mg 1 Capsule 318.01 4663(E) 25.10.2023 94 Ipratropium Inhalation (MDI/DPI) 20 mcg/dose 1 Dose 0.76 1573(E) 31.03.2023 95 Ipratropium Respirator solution for use in Nebulizer 250 mcg/ml 1 ml 3.15 1573(E) 31.03.2023 96 Ketamine Injection 10 mg/ml 1 ml 13.19 4663(E) 25.10.2023 97 Levonorgestrel Tablet 0.75 mg 1 Tablet 28.65 4663(E) 25.10.2023 98 Levothyroxine Tablet 37.50 mcg 1 Tablet 1.47 4663(E) 25.10.2023 99 Lignocaine (A) + Adrenaline (B) Injection 1% (A) + 1:200000 (5 mcg/ml) (B) 1 ml 0.56 1573(E) 31.03.2023 100 Lopinavir (A) + Ritonavir (B) Tablet 100 mg(A) + 25 mg(B) 1 Tablet 29.28 4663(E) 25.10.2023 101 Measles Rubbela Vaccine Each Pack (0.5ml) 110.07 4663(E) 25.10.2023 102 Measles vaccine Vaccine Each Pac k (0.5ml) 63.47 1573(E) 31.03.2023 103 Methotrexate Injection 50 mg/ml 1 ml 49.86 1573(E) 31.03.2023 104 Methylrosanilinium chloride (Gentian Violet) Paint 1% 1 ml 0.10 1573(E) 31.03.2023 105 Methylthioninium chloride (Methylene blue) Injection 10mg/ml 1 ML 27.13 1573(E) 31.03.2023 106 Midazolam Tablet 7.5mg 1 Tablet 27.94 1573(E) 31.03.2023 107 Morphine SR Tablet 30 mg 1 Tablet 6.78 1573(E) 31.03.2023 108 Morphine Tablet 10 mg 1 Tablet 6.63 4663(E) 25.10.2023 109 N-acetylcysteine Sachet 200mg 1 gm 11.20 1573(E) 31.03.2023 110 Nevirapine Oral Liquid 50 mg/5ml 1 ml 1.04 1573(E) 31.03.2023 111 Omeprazole Tablet 10 mg 1 Tablet 5.52 4663(E) 25.10.2023 112 Oral poliomyelitis vaccine 1 ml 127.67 1573(E) 31.03.2023 113 Oral Rehydration Salts As Lic ensed 1 gm 1.11 1573(E) 31.03.2023 114 Oxaliplatin Injection 100mg(as licensed) Each Pack 5563.91 4663(E) 25.10.2023 115 Para-aminosalicylic acid Granules (As licensed) 1 gm 3.54 1573(E) 31.03.2023 116 Paracetamol Injection 150 mg/ml Each Pack ( 0.5 m l) 3.82 1573(E) 31.03.2023 Sl. No. Medicines Dosage form and Strength Unit Ceilin g price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O. No. & Date (1) (2) (3) (4) (5) 6(a) 6(b) 117 Paracetamol Injection 150 mg/ml Each Pack (1 ml) 5.22 1573(E) 31.03.2023 118 Paracetamol Injection 150 mg/ml Each Pack (3 ml) 10.84 1573(E) 31.03.2023 119 Paracetamol Injection 150 mg/ml Each Pack (4 ml) 13.65 4663(E ) 25.10.2023 120 Paracetamol Injection 150 mg/ml Each Pack (5 ml) 16.46 4663(E) 25.10.2023 121 Paracetamol Injection 150 mg/ml Each Pack (7 ml) 22.07 4663(E) 25.10.2023 122 Penicillamine Capsule 250 mg 1 Capsule 18.50 1573(E) 31.03.2023 123 Phenyle phrine Drop 10% 1 ml 10.06 4663(E) 25.10.2023 124 Phenylephrine Drops 5% 1 ml 4.64 1573(E) 31.03.2023 125 Phenytoin ERCapsule 300 mg 1 Capsule 4.74 1573(E) 31.03.2023 126 Phenytoin injection 25 mg/ml 1 ml 3.13 4663(E) 25.10.2023 127 Pilocarpine Drops 4% 1 ml 14.54 1573(E) 31.03.2023 128 Potassium permanganate Crystals for topical solution 1 gm 0.55 4663(E) 25.10.2023 129 Povidone iodine Scrub 7.5% 1 ml 2.00 4663(E) 25.10.2023 130 Povidone iodine Ointment 10% 1 gm 6.48 1573(E) 31.03.2023 131 Praziq uantel Tablet 600 mg 1 tablet 43.25 4663(E) 25.10.2023 132 Prednisolone Injection 20 mg/2ml 1 ml 4.46 1573(E) 31.03.2023 133 Pyrazinamide Oral Liquid 250 mg/5ml 1 ml 0.76 1573(E) 31.03.2023 134 Rifampicin Tablet 150 mg 1 Tablet 2.01 4663(E) 25.10.2023 135 Rifampicin Tablet 300 mg 1 Tablet 3.66 4663(E) 25.10.2023 136 Ringer Lactate Injection 1000ml Each Pack 99.32 4663(E) 25.10.2023 137 Ringer Lactate Injection 100ml Each Pack 26.00 1573(E) 31.03.2023 138 Ringer Lactate Injection 250ml Each Pack 44.33 1573(E) 31.03.2023 139 Ringer Lactate Injection 500ml Each Pack 56.50 4663(E) 25.10.2023 140 Ritonavir Capsule 100 mg 1 Capsule 35.14 4663(E) 25.10.2023 141 Salbutamol Capsule 4 mg 1 Capsule 0.74 1573(E) 31.03.2023 142 Silver Sulphadiazine Cream 1% 1 gm 0.63 4663(E) 25.10.2023 143 Sodium Chloride Injection 0.9% 1000ml Glass 73.88 4663(E) 25.10.2023 144 Sodium Chloride Injection 0.9% 1000ml Non - Glass 58.27 4663(E) 25.10.2023 145 Sodium Chloride Injection 0.9% 100ml Glass 21.84 1573(E) 31.03.2023 146 Sodium Chloride Injection 0.9% 100ml Non - Glass 19.68 4663(E) 25.10.2023 147 Sodium Chloride Injection 0.9% 250ml Glass 29.47 4663(E) 25.10.2023 148 Sodium Chloride Injection 0.9% 250ml Non - Glass 26.45 4663(E) 25.10.2023 149 Sodium Chloride Injection 0.9% 500ml Glass 40.97 4663(E) 25.10.2023 150 Sodium Chloride Injection 0.9% 500ml Non - Glass 34.87 4663(E) 25.10.2023 151 Sodium nitrite Injection 30 mg/ml 1 ml 32.35 4663(E) 25.10.2023 152 Sodium Nitroprusside Injection 10 mg/ml 1 ml 32.15 4663( E) 25.10.2023 153 Streptokinase Injection 7,50,000 IU Each Pack 1567.42 4663(E) 25.10.2023 Sl. No. Medicines Dosage form and Strength Unit Ceilin g price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O. No. & Date (1) (2) (3) (4) (5) 6(a) 6(b) 154 Surfactant Suspension for intratracheal instillation (As liensed) Per mg of Phospholipids in the pack 83.27 1573(E) 31.03.2023 155 TD Vaccine Each dose of 0. 5ml contains: Diphtheria Toxoid ≤5Lf (≥ 2IU) Tetanus Toxoid ≥ 5Lf (≥ 40IU) Each 0.5ml Pack 23.33 1573(E) 31.03.2023 156 TD Vaccine Each dose of 0.5ml contains: Diphtheria Toxoid ≤5Lf (≥ 2IU) Tetanus Toxoid ≥ 5Lf (≥ 40IU) Each 5ml Pack 219.25 1573(E) 31.03 .2023 157 TD Vaccine Each dose of 0.5ml contains: Diphtheria Toxoid ≤25Lf (≥ 30IU) Tetanus Toxoid ≥ 5Lf (≥ 40IU) Each 0.5ml Pack 20.00 1573(E) 31.03.2023 158 Temozolomide Tablet 100 mg 1 Tablet 1925.59 4663(E) 25.10.2023 159 Timolol Drops 0.25% 1 ml 6.44 4663(E) 25.10.2023 160 Tramadol Injection 50 mg/ml (20 ml Pack) 1 ml 1.55 4663(E) 25.10.2023 161 Verapamil Injection 2.5 mg/ml 1 ml 1.46 4663(E) 25.10.2023 162 Vinblastine Injection 1mg/ml 1 ml 25.54 1573(E) 31.03.2023 163 Vitamin A Capsule 50000 IU 1 Capsule 0.68 1573(E) 31.03.2023 164 Water for Injection Injection Each Pack (10 ml) 2.89 1573(E) 31.03.2023 165 Water for Injection Injection Each Pack (5 ml) 2.79 1573(E) 31.03.2023 166 Water for Injection Injection Per 500 ml Pack 57.40 4663(E) 25.10.2023 167 Water for Injection Injection Per 1000 ml Pack 100.74 1573(E) 31.03.2023 168 Zidovudine Capsule 300 mg 1 Capsule 2.57 4663(E) 25.10.2023 169 Zolpidem Capsule 5 mg 1 Capsule 9.15 4663(E) 25.10.2023 Notes: - (a) The ceiling prices are applicabl e with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured the manufacturer s hall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its formulations. (c) In respect of any other scheduled formulation for which ceiling price is not mentioned above, themanufacturer shall approach NPPA for specific price approva l for its formulations. (d) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. (e) All the existing manufacturers of above -mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentio ned in column (5) of the above said table. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revision and non -submission of informa tion under this sub -paragraph shall be construed as non -revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereo n from the date of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in para graph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per pa ra 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessib le to any person wishing to consult the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufa cturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of productio n / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of disconti nuation of production and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified herein above shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director का. आ. 1549(अ).— 4, 6, 10, 11, 14, 4 ,16 ,17 a b 0.00551% ) (1) (2) (3) (4) (5) 6(a) 6(b) 1 ,lhVkby lkfyflfyd ,flM xksyh 300 fexzk 1 xksyh 0.28 1568( अ) 31-03-23 2 dSfY'k;e dkcksZusV xksyh 250 fexzk 1 xksyh 2.43 1568( अ) 31-03-23 3 daMksel 1 daMkse 11.37 4663( अ) 25-10-23 4 Msilksu xksyh 50 fexzk 1 xksyh 0.29 1568( अ) 31-03-23 5 esMªksDlh izksxsLVsjksu ,flVsV xksyh 5 fexzk 1 xksyh 3.72 1568(अ) 31-03-23 6 fjQefiflu xksyh 450 fexzk 1 xksyh 5.52 4663( अ) 25-10-23 - ( 0.00551% ) (5) 0.00551% (5) V (4) u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March , 2024 S.O. 1549 (E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) O rder, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Mi nistry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in co lumn (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and u nit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2024 with WPI @ 0.00551%) (in Rs.) Existing S.O. No. & Date (1) (2) (3) (4) (5) 6(a) 6(b) 1 Acetyl Salicylic Acid Tablet 300mg 1 Tablet 0.28 1568 (E) 31-03-23 2 Calcium carbonate Tablet 250 mg 1 Tablet 2.43 1568 (E) 31-03-23 3 Condoms 1 Condom 11.37 4663(E ) 25-10-23 4 Dapsone Tablet 50 mg 1 Tablet 0.29 1568 (E) 31-03-23 5 Medroxy Progesterone Acetate Tablet 5mg 1 Tablet 3.72 1568 (E) 31-03-23 6 Rifampicin Tablet 450mg 1 Tablet 5.52 4663(E) 25-10-23 Notes: - a) The ceiling prices are applicab le with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulation s at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. c) All the existing manufacturers of above -mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above tab le (plus Goods and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. d) The manufacturers may add Goods and S ervices Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. e) Information about the revision, if carried out, shall be forwarded to the Government in either electr onic or physical form in Form -II within a period of fifteen days of such revision and non -submission of information under this sub -paragraph shall be construed as non -revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragrap h 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufactu rer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as spe cified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. i) The manufac turers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontin ue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the inten ded date of discontinuation. j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 201 3 read with Essential Commodities Act, 1955. k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the a bove said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director का. आ. 1550(अ).— , 4, 6, 10, 11, 14, 16, 17 a b 0.00551% (1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b) 5.28 5.31 5.31 31015/21/202 3- 08.02.2024 1574(अ) 31-03-23 11.72 12.01 12.01 31015/12/202 3- 19.02.2024 4663(अ) 25-10-23 73.88 74.59 74.59 31015/13/202 3- 22.02.2024 4663(अ) 25-10-23 - (6) .03. ( @0.00551 % ) . . 0.00551 (6) (6) V (4) (1) u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March , 2024 S.O. 1550 (E).—In implementation of directions of review or ders issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order(s) specified in column (8) of the table below and i n exercise of the powers, co nferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Gove rnment of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 9(a) & 9(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes/revi ses the prices as specified in column (6) and further revised the prices w. e. f. 01.04.2024 specified in column (7) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulation s specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. No. Medicines Dosage form & Strength Unit Ceiling Price under NLEM, (Rs.) Revised ceiling price as per review order (in Rs.) Ceiling price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.) Review Order number and date Existing SO number and date (1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b) 1. Cefuroxime Oral liquid 125mg/5mL(p) 1 ML 5.28 5.31 5.31 31015/21/2023 -Pricing dated 08.02.2024 1574 (E) 31-03-23 2. Montelukast Tablet 5 mg (including chewable Tablet s) 1 Tablet 11.72 12.01 12.01 31015/12/2023 -Pricing dated 19.02.2024 4663 (E) 25-10-23 3. Mycopheno l ate mofetil Tablet 500mg 1 Tablet 73.88 74.59 74.59 31015/13/2023 -Pricing dated 22.02.2024 4663 (E) 25-10-23 Notes: - (a) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) as fixed and notified by the Government as specified in column (6) of the above table, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (6) plus Goods and Services Taxes as applicable, if any. (b) All the existing manufacturers of above -mentioned scheduled formulations having MRP lower than the ceiling price as specified in column (6) in the above table (plus Goods and Services Tax es as applicable, if any) shall continue to maintain the existing MRP in accordance with para 13(2) of DPCO,2013 till 31.03.2024. (c) The ceiling prices as specified in column (7) of the table are applicable with effect from 01.04.2024 (ceiling prices are in clusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). All the existing manufacturers of above -mentioned scheduled formulations having MRP lower or equal than the ceiling price as specified in column (6), as on 31.03.2024, in the a bove table (plus Goods and Services Taxes as applicable, if any) may revise the MRP on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Taxes only if they ha ve paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) and/or (7) of the above said table. (e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical f orm in Form -II within a period of fifteen days of such revision and non -submission of information under this sub -paragraph shall be construed as non -revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) and/or (7) applicable of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per para graph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manuf acturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as spe cified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (i) The manufacture rs of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue produ ction of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said d ate of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director का. आ. 1551(अ).— , , . . , . . , . . , . . , . . . . @ 0.00551% , , I 0.00551% 01.04.2024 िे 10509.79 38267.18 - 13(2) @ 0.00551% (4) [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March , 2024 S.O. 1551 (E).—In continuation of the notifications issued by National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated 12.02.2018, S.O. 1464(E ) dated 02.04.2018, S.O. 1488(E) dated 29.03.2019, SO. 1217(E) dated 25.03.2020, S.O. 1334(E) dated 25.03.2021, 1502(E) dated 30.03.2022, 5249(E) dated 11.11.2022, 1572(E) dated 31.03.2023 and 4663(E) dated 25.10.2023 regarding the fixation of ceiling pric e of the Coronary Stents as specified in column no. (2) mentioned in the table below; after considering the Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022, it has been decided to revise the ceiling prices of Coronary Stents as me ntioned in column no. (4) in the table below, exclusive of Goods and Services Tax as applicable,and unit specified in column (3) with effect from 01.04.2024, as under: TABLE Sl. No . Coronary Stents (Sl. No. 28 in Schedule -I of the DPCO, 2013) Unit (in Num ber) Ceiling price (wef 1.4.2024 with WPI @0.00551%) (in Rs.) (1) (2) (3) (4) 1 Bare Metal Stents 1 10509.79 2 Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents 1 38267.18 Notes: - (a) All the existing manufacturers/importers of Coronary Stents having MRP lower than the ceiling price specified in column (4) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of Coronary Stent, on the basis of WP I @ 0.00551 % for the year 2023 over 2022 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013. (b) The manufacturers/importers of Coronary Stents may add Goods and Services Taxes only if they have paid actually or if it is paya ble to the Government on the ceiling price mentioned in column (4) of the aforesaid table. (c) As per Para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer/im porters, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (d) The manufacturers not complying with the ceiling price and notes specified hereinabove sha ll be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955 [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director का. आ. 1552(अ).—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk -vk- 1394¼v½ rkjh[k 30 ebZ] 2013] dk -vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk -vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½ , iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds 'kqf)&i= vkns'k dk - vk- 1500¼v½ fnukad 30 ekpZ] 2022, dk-vk- 4591¼v½ fnukad 29.09.2022, dk-vk- 1571¼v½ fnukad 31.03.2023, dk-vk- 4663¼v½ fnukad 25.10.2023, dk-vk- 4887¼v½ fnukad 10.11.2023 vkSj dk-vk- 424¼v½ fnukad 02.02.2024 vkns'k ds vf/kØe.k esa tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d* esa fofufeZr iSd ] uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks”k mRikn ,oa iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la”kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSds ftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj ] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i esa fu;r djrh gSA @ 0.00551 % (1) (2) (3) (4) (5) 1 Xywdkst batsD”ku 5% 1000 fefy xSj&dk¡p fo'ks"k fo'ks’krkvksa lfgr 95.11 2 Xywdkst batsD”ku 5% 500 fefy xSj&dk¡p fo'ks"k fo'ks’krkvksa lfgr 82.27 3 Xywdkst ¼,½$lksfM;e DyksjkbM ¼ch½ batsD”ku 5% ¼,½$0-9% ¼ch½ 1000 fefy xSj&dk¡p fo'ks"k fo'ks’krkvksa lfgr 99.94 4 Xywdkst ¼,½$lksfM;e DyksjkbM ¼ch½ batsD”ku 5% ¼,½$ 0- 9% ¼ch½ 500 fefy xSj&dk¡p fo'k s"k fo'ks’krkvksa lfgr 85.52 5 lksfM;e DyksjkbM batsD”ku 0 -9% 100 fefy xSj&dk¡p fo'ks"k fo'ks’krkvksa lfgr 42.06 6 lksfM;e DyksjkbM batsD”ku 0 -9% 250 fefy xSj&dk¡p fo'ks"k fo'ks”krkvksa lfgr 62.10 7 lksfM;e DyksjkbM batsD”ku 0 -9% 500 fefy xSj&dk¡p fo'ks "k fo'ks’krkvksa lfgr 87.94 8 lksfM;e DyksjkbM batsD”ku 0 -9% 1000 fefy xSj&dk¡p fo'ks"k fo'ks’krkvksa lfgr 98.51 0.00551% (5) dk- vk- 1571¼v½ fnukad 31 .03.2023, dk-vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4887¼v½ fnukad 10.11.2023 vkSj dk-vk- 424¼v½ fnukad 02 .02.2024 0.00551% (5) V (4) (1) u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March , 2024 S.O. 1552 (E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1571(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4887(E) dated 10.11.2023 and 424(E) dated 02.02.2024 in so far as they relate to formulation packs mentioned in t he Table A below, manufactured by the manufacturers specified in Table B for specified products and pack -sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corres ponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.005 51% increase Sl. No. Medicines Dosage form and Strength Unit Ceiling price (w.e.f.01.04.2024 with WPI @ 0.00551 %) (in Rs.) (1) (2) (3) (4) (5) 1 Glucose Injection 5% 1000ml NonGlass with special features 95.11 2 Glucose Injection 5% 500ml Non Glass wi th special features 82.27 3 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 1000ml Non Glass with special features 99.94 4 Glucose (A) + Sodium Chloride (B) Injection 5% (A) + 0.9% (B) 500ml Non Glass with special features 85.52 5 Sodium Chloride Injection 0.9% 100ml Non Glass with special features 42.06 6 Sodium Chloride Injection 0.9% 250ml Non Glass with special features 62.10 7 Sodium Chloride Injection 0.9% 500ml Non Glass with special features 87.94 8 Sodium Chloride Injectio n 0.9% 1000ml Non Glass with special features 98.51 TABLE B Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s B.Braun Medical (I) Pvt Ltd. Ecoflac Plus bottle with Eurohead 2 M/s Amanta Healthcare Ltd. Steriport bottle 3 M/s Aculife Healthcare Pvt Ltd. Aculife bottle with Eurohead 4 M/s Albert David Limited Albert David bottle with Eurohead 5 M/s Denis Chem Limited Aquapulse with Eurohead 6 M/s Claris Life Sciences Limited Claris bottle with Eurohead 7 M/s Fresenius Kabi India Pvt Limited Freeflex bags 8 M/s Otsuka Pharmaceutical India Private Ltd. (previously known as Claris Otsuka Private Limited) Unibag 9 M/s Aishwarya Lifesciences LifusionEurohead bottle 10 M/s Baxter (India) Pvt. Ltd. Viaflex bags 11 M/s Otsuka Pharmaceuti cal India Private Ltd. (previously known as Claris Otsuka Private Limited) Eurohead bottle 12 M/s Fresenius Kabi India Pvt Limited Eurohead bottle 13 M/s Axa Parenterals Ltd Steri Drip bottle with Eurohead 14 M/s Shree Krishna Keshav Laboratories Ltd Easyport bottle with Eurohead 15 M/s Rusoma Laboratories Pvt. Ltd. Puradrip 16 M/s R. K. Laboratories Pvt. Ltd. Eurohead bottle 17 M/s Eurolife Healthcare Pvt. Ltd. Life port 18 M/s RealcadeLifesciencePvt. Ltd. Euro head bottle 19 M/s Puniska Healthcare Pvt. Ltd [Note (b) below] Non –PVC bag 20 M/s Abaris Healthcare Pvt. Ltd Duo Port 21 M/s Higgs Healthcare [Note (c) below] Aqua Drip 22 M/s Rusoma Laboratories Pvt. Ltd. Eurohead Bottles with Brand name “Dewdrip” 23 M/s Puerto life Sciences Private Limited [Note (d) below] Euro head bottle 24 M/s Sachin Parenteral Pvt. Ltd. [Note (e) below] “SAFE PORT” 25 M/s Biosynergy Lifecare Pvt. Ltd. [Note (f) below] “BIOPORT” 26. M/s Promea Therapeutics Pvt. Ltd. [Note (g) below] LDPE Bottle/ Non -Glass cont ainer with special features Euro head Cap Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) In case of M/s Puniska Healthcare Pvt. Ltd .mentioned in Sl. No. 19 of Table B, only the prices of the formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable. (c) In case of M/s Higgs Healthcare mentioned in Sl. No. 21 of Table B, only the prices of the formulations specified in Sl. No . 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable. (d) In case of M/s Puerto life Sciences Private Limited mentioned in Sl. No. 23 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable. (e) In case of M/s Sachin Parenteral Pvt. Ltd. mentioned in Sl. No. 24 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5, 6 & 7 of Table A are applicable. (f) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 25 of Table B, only the prices of the formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable . (g) In case of M/s Promea Therapeutics Pvt. Ltd. mentioned in Sl. No. 26 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are appli cable. (h) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the p rices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (i) The manufacturers of above -mentioned scheduled formulations having MRP lower than the ceil ing price notified vide S.O. No. 1571(E) dated 31.03.2023, S.O. 4663 (E) dated 25.10.2023, S.O. No. 4887(E) dated 10.11.2023 and S.O. No. 424(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their fo rmulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (j) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (k) Any other manufacturer claiming separate ceiling price for Non -Glass with special feature shall apply to NPPA for separate ceiling price approval with details and demonstrate, that such pack alongwith docum entation and demonstration. (l) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revision and non -submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (m) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (n) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (o) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (p) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production a nd / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (q) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (r) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director का. आ. 1553(अ).—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk -vk- 1394¼v½ rkjh[k 30 ebZ] 2013] dk -vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk -vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=. k½ vkns'k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½ , iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k dk - vk- 1570¼v½ fnukad 31 ekpZ] 2023 , dk- vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4888¼v½ fnukad 10.11.2023 vkSj dk- vk- 425¼v½ fnukad 02.02.2024 , vkns'k ds vf/kØe.k esa tgk¡ rd , uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks”k mRikn ,oa iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls v f/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la”kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks m Dr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i esa fu;r djrh gSA @ 0.00551% बढा @ 0.00551 % (1) (2) (3) (4) (5) (1) (2) 0.00551 % ( 19) (5) dk- vk- 1570¼v½ fnukad 31 ekpZ] 2023 , dk- vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4888¼v½ fnukad 10.11.2023 vkSj dk- vk- 425¼v½ fnukad 02.02.2024 0.00551 % (5) V (4) (1) u II I II III II IV [dka- la-@254@122@2024@,Q@Qk - la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March , 2024 S.O. 1553 (E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dat ed 22nd March, 2016, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Ph armaceutical Pricing Authority) S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. 4888(E) dated 10.11.2023 and S.O. 425(E) dated 02.02.2024 in so far as it relates to formulation packs mentioned in the Table A below, manufactured by the m anufacturers specified in Table B for specified products and pack -sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage for m and Strength Unit Ceiling price (w.e.f.01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Ringer lactate Injection100 ml Each 100 ml pack having special features 29.90 2 Ringer lactate Injection 250 ml Each 250 ml pack having special features 50.99 3 Ringer lactate Injection 500 ml Each 500 ml pack having special features 64.96 4 Ringer lactate Injection 1000 ml Each 1000 ml pack having special features 114.21 TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s Albert David Ltd. Eurohead 2 M/s Aculife Healthcare Pvt. Ltd. Eurohead 3 M/s B. Braun Medical (India) Pvt. Ltd. Ecoflac Plus bottle with Eurohead 4 M/s Fresenius Kabi India Pvt. Ltd. Freeflex bags 5 M/s Ostuka Pharmaceuticals India Pvt. Ltd. Eurohea d bottle 6 M/s Denis Chem lab Ltd. Eurohead Propylene Bottle 7 M/s Amanta Healthcare Ltd. FFS/BFS 8 M/s Shree Krishna Keshav Laboratories Ltd. Eurohead 9 M/s AxaParenterals Ltd. Steridip with Eurohead 10 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle 11 M/s R. K. Laboratories Pvt. Ltd. Eurohead Bottle 12 M/s Realcade Lifescience Pvt. Ltd. Non-glass with special features 13 M/s Abaris Healthcare Pvt. Ltd (Note (b) below) Non-glass with special features 14 M/s Higgs Healthcare (Note (c) below) Non-glass with special features 15 M/s Rusoma Laboratories Pvt. Ltd. (Note (b) below) “Dewdrip” 16 M/s Puerto life Sciences Private Limited (Note (d) below) Eurohead bottle 17 M/s Sachin Parenteral Pvt. Ltd. (Note (d) below) “SAFE PORT” 18 M/s Biosyne rgy Lifecare Pvt. Ltd. (Note (e) below) “BIOPORT” 19 M/s Promea Therapeutics Pvt. Ltd. (Note (d) below) PROCAP -RL Notes: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551 % for the year 2023 over 2022). (b) In case of M/s Abaris Healthcare Pvt. Ltd. (Sl. No. 13 of Table B) & M/s Rusoma Laboratories Pvt. Ltd. (Sl. No. 15 of Table B), only the prices of the formulations specified in Sl. No. 2, 3 & 4 of Table A are applicable. (c) In case of M/s Higgs Healthcare mentioned in Sl. No. 14 of Table B, only the prices of the formulations specified in Sl. No. 3 & 4 of Table A are applicable. (d) In case of M/s Puerto life Sciences Private Limited (Sl. No. 16 of Table B), M/s Sachin Parenteral Pvt. Ltd. (Sl. No. 17 of Table B) & M/s Promea Therapeutics Pvt. Ltd. (Sl. No. 19 of Table B), only the prices of the formulations specified in Sl. No. 3 of Table A are applicable. (e) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 18 of T able B, only the prices of the formulations specified in Sl. No. 3 & 4 of Table A are applicable (f) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any . (g) The manufacturers of above -mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. 4888(E) dated 10.11.2023 and S.O. 425(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over the year 2022 in accordance with paragraph 16(2) of DPCO, 2013. (h) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (i) Any other manufacturer claiming separate ceiling price for ringer lactate injection in pack having special features shall apply to NPPA for separate ceiling price approval. (j) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revision and non -submissi on of information under this sub -paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith in terest thereon from the date of overcharging. (k) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions cont ained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealer s. (l) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be eas ily accessible to any person wishing to consult the same. (m) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (n) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of pro duction / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of di scontinuation of production and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (o) The manufacturers not complying with the ceiling price and notes specified h ereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (p) Consequent to the issue of ceiling prices of such formulation s as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh] 26 ekpZ] 2024 ¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk -vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk -vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a =.k½ vkns'k] 2013 ds iSjk 11 ds mi&iSjk ¼3½ vkSj ¼ 4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/k kZj.k izkf/kdj.k½ ds vkns'k dk -vk- 4077¼v½ fnukad 15 .09.2023 vkns'k ds vf/kØe.k esa tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d* esa fofufeZr से gSA uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo"ks' k mRikn ,oa iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; l wpdkad ¼MC Y;wihvkbZ½] 2023 ij vk/kkfjr la' kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV ½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj ] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i esa fu;r djrh gSA @ 0.00551% (@ 0.00551% (1) (2) (3) (4) (5) fo'ks"k fo'ks’krkvksa lfgr 220.27 fo'ks’krkvksa lfgr 459.31 (3) 0.00551% 15.09.2023 0.00551% u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March, 2024 S.O. 1554 (E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 20 13, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pric ing Authority) S.O. No. 4077(E) dated 15.09.2023 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack -sizes, except in respect of things done or o mitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entri es in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Piperacillin (A) + Tazobactam (B) Powder for Injection 2 g (A) + 250 mg(B) Per Dual chamber bag with special feature 220.27 2 Piperacillin (A) + Tazobactam (B) Powder for Injection 4 g (A) + 500 mg(B) Per Dual chamber bag with special feature 459.31 TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s Gufic Biosciences Limited Tazofic Injection (DCB) Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI ) @ 0.00551% for the year 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above -mentioned schedul ed formulations having MRP lower than the ceiling price notified vide S.O. No. 4077(E) dated 15.09.2023 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Piperacillin (A) + Tazobactam (B) Injection (i) Powder for injection 2g (A) + 250gm (B) (ii) 4g (A) + 500gm (B) Per Dual chamber bag having special features shall apply to NPPA for separate ceilin g price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revision and non -submission of information under this sub -paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereon from the date of ov ercharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the D rugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (h) As per para 24(4) of DP CO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any pers on wishing to consult the same. (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall ap ply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import a nd sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of p roduction and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying with the ceiling price and notes specified hereinabove sha ll be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to the issue of ceiling prices of such formulations as speci fied in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh] 26 ] 2024 ¼v½.— 31.03.2023, 31.03.2023, 25.10.2023, 10.11.2023 02.02.2024 0.00551% (@ 0.0 0551% (1) (2) (3) (4) (5) 0.25 0.00551% 31.03.2023, 25.10.2023, 10.11.2023 02.02.2024 0.00551% u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March, 2024 S.O. 1555 (E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 20 13, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pric ing Authority) S.O. No. 1576(E) dated 31.03.2023, 1584(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated 10.11.2023 and 426(E) dated 02.02.2024 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manuf acturers specified in Table B for specified products and pack -sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (W PI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Ta ble with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Metronidazole Injection (0.5%w/v) /500mg/100ml in 100ml pack for packages in non - glass with special features Per ml 0.25 TABLE ‘B’ Sl. No. Name of Manu facturer Product /Brand Name (1) (2) (3) 1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle 2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle 3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle 4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT” 5 M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT” 6 M/s Promea Therapeutics Pvt. Ltd. PROCAP -MT Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the y ear 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government , shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above -mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1576(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated 10.11.2023 and 426(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their f ormulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Metronidazole Injection (0.5%w/v) /500mg/ 100ml in 100ml pack for packages in non -glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revi sion and non -submission of information under this sub -paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail pric e (MRP), alongwith interest thereon from the date of overcharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above tab le as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State D rug Controller and dealers. (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on busines s in a manner so as to be easily accessible to any person wishing to consult the same. (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u ) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish info rmation to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying wit h the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to th e issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/ 122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh] 26 ] 2024 ¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk -vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk -vk- 5249¼v½ rkjh[k 11 uoEcj] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k dk - vk- 1575¼v½ fnukad 31.03.2023, dk-vk- 1583¼v½ fnukad 31.03.2023 vkSj dk-vk- 4890¼v½ fnukad 10.11.2023 vkns'k ds vf/kØe.k esa tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d* ls lacaf/kr gSA uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrk sa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MC Y;wihvkbZ½] 2023 ij vk/kkfjr la' kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr f ofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i esa fu;r djrh gSA 0.00551% (@ 0.00551% (1) (2) (3) (4) (5) @0.00551% 31.03.2023, 31.03.2023 10.11.2023 0.00551% u II I II III II IV [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March, 2024 S.O. 1556 (E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2 013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pri cing Authority) S.O. No. 1575(E) dated 31.03.2023, S. O. No. 1583(E) dated 31.03.2023 and S.O. No. 4890(E) dated 10.11.2023 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack -sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2023 as specifi ed in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage fo rm and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and Strength Unit Ceili ng pr ice (wef 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Mannitol Injection 20% in 100 ml pack for packages in non-glass with special features Per ml 0.40 TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s. Otsuka Pharmaceutical India Private Ltd. Eurohead bottle 2 M/s. Denis Chem Lab Ltd. Eurohead Propylene Bottle 3 M/s. Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle 4 M/s. Sachin Parenteral Pvt. Ltd. “SAFE PORT” 5 M/s. Biosynergy Lifecare Pvt. Ltd . “BIOPORT” Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid p roducts/brandnameof scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above -mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1575(E) dated 31.03.2023, S.O. No. 1587(E) dated 31.03.2023 and S.O. No. 4890(E) dated 10.11.2023 read with corrigendum (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accor dance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufac turer claiming separate ceiling price for Mannitol Injection 20% in 100 ml pack for packages in non -glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revision and non -submission of information under this sub -paragraph shall be construed as non revision o f maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufa cturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall disp lay price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formul ation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amoun t along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh ] 26 ] 2024 ¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk -vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk -vk- 5249¼v½ rkjh[k 22 uoEcj] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds mi&iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izk f/kdj.k½ ds 'kqf)&i= vkns'k dk -vk- 1569¼v½ fnukad 31.03.2023, dk-vk- 4891¼v½ fnukad 10.11.2023 vkSj dk-vk- 427¼v½ fnukad 02.02.2024 vkns'k ds vf/kØe.k esa tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d*] uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks" k mRikn ,oa iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; v kS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MC Y;wihvkbZ½] 2023 ij vk/kkfjr la' kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V; ksa esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ"V vuqlwfpr fofufeZfr;ksa esa ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i esa fu;r djrh gSA 0.00551% (@ 0.00551% (1) (2) (3) (4) (5) 0.00551% 31.03.2023, 10.11.2023 02.02.2024 0.00551% V u II I II III II IV (ड) bl vkns’k esa mijksDr lkj.kh ds LraH k ¼2½ esa dh xbZ rRLFkkuh izfof"V esa fofufnZ" V ,slh fofufeZfr;ksa ds iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns’k] ;fn dksbZ gks] tks bl vkns’k ls iwoZ tkjh gq, gSa] Lor% gh vf/kØe.k gks tk;saxsA [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh&II] ORDER New Delhi, the 26th March, 2024 S.O. 1557 (E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated 02.02.2024 in so far as they relate to formulation packs mentio ned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack -sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: Table A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Dextrose (Glucose) Injection (25% w/v) in 100 ml pack for packages in non -glass with special features Per ml 0.24 TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle 2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle 3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottl e 4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT” 5. M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT” 6. M/s Promea Therapeutics Pvt. Ltd. PROCAP -D25 Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Who lesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applica ble) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of a bove -mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O.No. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Dextrose (Glucose) Injection (25% w/v) in 100 ml pack for packages in non -glass container in plastic bottle wit h euro head having special features shall apply to NPPA for separate ceiling price approval. (f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach NPPA for specific price approval for its formulation. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form -II within a period of fifteen days of such revision and non -submission of information under this sub -paragraph shall be co nstrued as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre -revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control ) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per para 24(4) of DPCO 2013, every retai ler and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consul t the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to depo sit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) o f the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant D irector ubZ fnYyh] 26 ] 2024 (1) (2) (3) (4) (5) (6) 14.00 15.32 15.32 14.00 14.60 (1) (2) (3) (4) (5) (6) 13.03 8.97 0.95 3.70 28.49 (1) (2) (3) (4) (5) (6) 3.17 7.92 9.60 (1) (2) (3) (4) (5) (6) 19.46 13.84 26.88 (1) (2) (3) (4) (5) (6) 9.67 10.78 (1) (2) (3) (4) (5) (6) (1) (2) (3) (4) (5) (6) (1) (2) (3) (4) (5) (6) (1) (2) (3) (4) (5) (6) 140.09 [dka- la-@254@122@202 4@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March, 2024 S.O. 1558 (E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as s pecified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manuf acturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1 Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydroc hloride IP 500mg (Sustained Release Form) 1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. 14.00 2 Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet Each film coated Bilayered Tablet Contain : Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) 1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. 15.32 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 3 Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet Each film coated Bilayered Tablet Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) 1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd. 15.32 4 Sitagliptin, Pioglitazone and Metformin Hydrochloride (Sustained Released) Tablet Each film coated Bilayered Tabl et Contain: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) 1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd. 14.00 5 Metoprolol Succinate Extended Release, Amlodipine and Telmisartan Tablet Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended release) Amlodipine Besilate IP eq. to Amlodipi ne 5mg Telmisartan IP 40mg 1 Tablet M/s Ajanta Pharma Limited / M/s Sun Pharma Laboratories Limited 14.60 6 Linagliptin & Metformin Hydrochloride (Extended Release) Tablets Each film coated bilayered tablet contains: Linagliptin IP 5mgMetformin Hydrochlor ide IP 500mg (As Extended release) 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Lupin Limited 13.03 7 Vitamin D3 (Cholecalciferol) Oral Solution Each 5 ml syrup contains: Cholecalciferol IP 60000IU 1 ml M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Emcure Pharmaceuticals Limited 12.53 8 Cholecalciferol (Vitamin D3) Oral Solution 60000IU Each 5ml contains: Cholecalciferol IP (In nano Droplet form) 60000IU 1 ml M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd. 13.60 9 Linagliptin + Metfor min Hydrochloride Tablet Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 500mg 1 Tablet M/s Morepen Laboratories Limited 8.97 10 Phenylephrine Hydrochloride, Each 5 ml contains: 1 ml M/s Tirupati Medicare Limited / M/s Macleods 0.95 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) Chlorpheniramine maleate, Paracetamol, Sodium Citrate & Menthol Syrup Phenylephrine Hydrochloride IP 5mg Chlorpheniramine maleate IP 0.5mg Paracetamol IP 125mg Sodium Citrate IP 60mg Menthol IP 1mg Pharmaceuticals Limited 11 Paracetamol, Phenylephrine Hydrochloride, Caffeine & Diphenhydramine Hydrochloride Tablet Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 5mg Caffeine (Anhydrous) IP 30mg Diphenhydramine Hydrochloride IP 25mg 1 Tablet M/s Aagya Biote ch Pvt. Ltd. / M/s Macleods Pharmaceuticals Limited 3.70 12 Linagliptin & Metformin Hydrochloride (Extended Release) Tablets Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 500mg 1 Tablet M/s M ascot Health Series Pvt. Ltd. / M/s Micro Labs Ltd. 11.60 13 Cefpodoxime & Potassium Clavulanate Tablets Each film coated tablet contains: Cefpodoxime Proxetil IP eq. to Anhydrous Cefpodoxime 200mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 1 25mg 1 Tablet M/s Brooks Laboratories Ltd. / M/s German Remedies Pharmaceuticals Private Limited 28.49 14 Cefpodoxime Proxetil & Potassium Clavulanate Oral suspension Each 5ml reconstituted suspension contains: Cefpodoxime Proxetil IP eq. to Anhydrous Cef podoxime 100mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 62.50mg 1 ml M/s Brooks Laboratories Ltd. / M/s German Remedies Pharmaceuticals Private Limited 4.94 15 Cilnidipine and Telmisartan Tablets Each film coated tablet contains: Cilnidipin e IP 10mg Telmisartan IP 40mg 1 Tablet M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cadila Pharmaceuticals Ltd. 10.26 16 Mefenamic Acid & Paracetamol Tablets Each uncoated tablet contains: Mefenamic Acid IP 500mg Paracetamol IP 325mg 1 Tablet M/s Mascot H ealth Series Pvt. Ltd. / M/s Micro Labs Limited 3.58 17 Pantoprazole & Domperidone Tablet Each enteric coated tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 40mg Domperidone IP 10mg 1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Zuvent us Healthcare Limited 7.04 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 18 Cefpodoxime & Potassium Clavulanate Oral suspension Each 5ml of reconstituted suspension contains: Cefpodoxime Proxetil IP eq. to Anhydrous Cefpodoxime 50mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 31.25mg 1 ml M/s Brooks Laboratories Ltd. / M/s German Remedies Pharmaceuticals Private Limited 3.17 19 Amoxycillin and Potassium Clavulanate Tablets IP Each film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 250mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg 1 Tablet M/s Malik Lifesciences Pvt. Ltd. / Themis Medicare Ltd. 17.46 20 Amoxycillin and Potassium Clavulanate Oral suspenssion Each 5ml of Reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 6 00mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg 1 ml M/s Malik Lifesciences Pvt. Ltd. / Themis Medicare Ltd. 3.18 21 Aceclofenac, Paracetamol & Thiocolchicoside Tablets Each film coated tablet contains: Aceclofenac IP 100mg Paracetamo l IP 325mg Thiocolchicoside IP 4mg 1 Tablet M/s Theon Pharmaceuticals Ltd. / M/s J.B. Chemicals & Pharmaceuticals Ltd. 17.84 22 Linagliptin + Metformin Hydrochloride Tablet Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochlorid e IP 850mg 1 Tablet M/s Morepen Laboratories Limited 7.92 23 Linagliptin + Metformin Hydrochloride Tablet Each film coated tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg 1 Tablet M/s Morepen Laboratories Limited 9.60 24 Rosu vastatin + Clopidogrel Capsules Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (as light orange coloured film coated tablet) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two, light brown coloured film coated tablets, each containing clopidogrel Tablet 37.5mg 1 Capsule M/s Windlas Biotech Ltd. / M/s Emcue Pharmaceuticals Limited 17.03 25 Rosuvastatin + Clopidogrel Capsules Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as light 1 Capsule M/s Windlas Biotech Ltd. / M/s Emcue Pharmaceuticals Limited 19.46 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) orange coloured film coated tablet) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two, light brown coloured film coated tablets, each containing clopidogrel Tablet 37.5mg 26 Atorvastatin and Fenofibrate Tablets Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg Fenofibrate IP 160mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited 27.09 27 Atorvastatin, Clopi dogrel & Aspirin Capsule Each hard gelatine capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As green coloured pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two reddish brown coloured film coated tablet, each containg 37.5mg Clopidogrel Tablets IP), Aspirin IP 75mg (As enteric coated white -coloured pellets) 1 Capsule M/s Windlas Biotech Limited / M/s Eris Lifesciences Ltd. 13.84 28 Atorvastatin & Clopidogrel Capsule Each hard gelatine capsule contains: Atorvastatin Calc ium IP eq. to Atorvastatin 40mg (As green coloured spherical pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two reddish brown coloured film coated tablet, each containg 37.5mg Clopidogrel Tablets IP), 1 Capsule M/s Windlas Biotech Limited / M/s Eris Lifesciences Ltd. 26.88 29 Gliclazide & Metformin Hydrochloride Tablets Each uncoated tablets contains: Gliclazide IP 40mg Metformin Hydrochloride IP 500mg 1 Tablet M/s Mediforce Healthcare Pvt ltd / M/s Mankind Pharma Ltd 7.35 30 Vildagliptin (SR) & Metformin Hydrochloride (SR) Tablets Each uncoated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained release form) Metformin Hydrochloride IP 500mg (As Sustained release form) 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s USV Priva te Limited 9.67 31 Vildagliptin (SR) & Metformin Hydrochloride (SR) Each uncoated bilayered tablet contains: Vildagliptin IP 100mg (As 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s USV Private Limited 10.78 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) Tablets Sustained release form) Metformin Hydrochloride IP 1000mg (As Sustained release form) 32 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochlor ide IP 500mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Alkem Laboratories Limited 13.24 33 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered table t contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited 13.24 34 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited 14.92 35 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydr ochloride IP 500mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s USV Private Limited 13.43 36 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s USV Private Limited 15.11 37 Dapagliflozin, Metformin Hydrochlo ride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Mankind Pharma Ltd. 15.11 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 500mg (As Extended release) Glimepiride IP 2 mg 38 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Mankind Pharma Ltd. 13.43 39 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Micro Labs Limited 12.50 40 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M /s Micro Labs Limited 13.39 41 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Exten ded release) Glimepiride IP 1 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Medley Pharmaceuticals Ltd. 13.43 42 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapaglifl ozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Medley Pharmaceuticals Ltd. 15.11 43 Dapagliflozin, Metformin Hydrochloride (Extend ed Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Lupin Limited 13.43 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) Glimepiride IP 1 mg 44 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Lupin Limited 15.11 45 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Windlas Biotech Limited / M/s Emcure Pharmaceuticals Limited 14.44 46 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Windlas Biotech Limited / M/s Emcure Pharmaceuticals Limited 16.12 47 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 m g 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Micro Labs Limited 14.29 48 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozi n 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Micro Labs Limited 15.18 49 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film co ated bilayered tablet contains: Dapagliflozin Propanediol eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. / Dr. Reddy's Laboratories Limited 14.55 50 Dapagliflozin, Metformin Hydrochloride Each film coated bilayered tablet contains: 1 Tab let M/s Akums Drugs & Pharmaceuticals Ltd. / Dr. Reddy's Laboratories 16.23 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) (Extended Release) and Glimepiride Tablets Dapagliflozin Propanediol eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg Limited 51 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapag liflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. 13.39 52 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glim epiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Blue Cro ss Laboratories Pvt. Ltd. 14.29 53 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg 1 Tablet M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. 16.00 54 Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg 1 Tablet M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd. 14.55 55 Dapagliflozin, Metformin Hydro chloride and Glimepiride Tablets Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate IP eq. to Dapagliflozin 5mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg 1 Tablet M/s Sun Pharma Laboratories Limited 12.98 56 Dapagliflozin, Metformin Hydrochloride and Glimepiride Tablets Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate IP eq. to Dapagliflozin 5mg 1 Tablet M/s Sun Pharma Laboratories Limited 11.30 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg 57 Dapagliflozin, Metformin Hydrochloride and Glimepiride Tablets Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate IP eq. to Dapagliflozin 5mg Metformin Hydrochloride IP 500mg Glimepiride IP 1 mg 1 Tablet M/s Sun Pharma Laboratories L imited 9.91 58 Dapagliflozin, Metformin Hydrochloride and Glimepiride Tablets Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate IP eq. to Dapagliflozin 5mg Metformin Hydrochloride IP 500mg Glimepiride IP 2 mg 1 Tablet M/s Sun Pharma Laboratories Limited 11.59 59 Azelnidipine and Metoprolol Succinate (Sustained Release) Tablet Each film coated bilayered tablet contains: Azelnidipine IP 16mg Metoprolol Succinate IP eq. to Metoprolol Tartrate 25mg (as Sustained release) 1 Tablet M/s Aku ms Drugs & Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. 15.92 60 Azelnidipine and Metoprolol Succinate (Sustained Release) Tablet Each film coated bilayered tablet contains: Azelnidipine IP 16mg Metoprolol Succinate IP eq. to Metoprolol Tartrat e 50mg (as Sustained release) 1 Tablet M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. 17.23 61 Mecobalamin, Zinc, Calcium Pantothenate, Vitamin B6, Folic Acid, Niacinamide & Chromium Tablets Each film coated tablet contains: Mecobalamin IP 500mcg Zinc Sulphate Monohydrate IP 61.8mg (eq. to elemental Zinc 22.5mg) Calcium Pantothenate IP 10mg Pyridoxine Hydrochloride IP 3mg Folic Acid IP 1.5mg Niacinamide IP 50mg Chromium 50mcg (As Chromium Picolinate IP) 1 Tablet M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Blue Cross Laboratories Private Limited 4.97 62 Ceftriaxone and Sulbactam injection Each Combi pack Contains: Part -I Each vial contains: 1 Vial M/s East African (India) Overseas / M/s Softdeal Pharmaceuticals Private 140.09 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) Ceftriaxone Sodium IP (Sterile) eq. to anhydrous Ceftriaxone 1000mg, Sulbactam Sodium IP ( Sterile) eq. to Sulbactam 500mg Part -II (For Reconstitution) Each FFS Ampoule contains: Sterile Water for Injection IP 10ml Limited Note: (a) The manufacturer of above -mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in c olumn (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on busin ess in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting F orm-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competen t Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and n otes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Conseq uent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) f ixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded. [PN/254/ 122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh] 26 ] 2024 ¼ .— (1) (2) (3) (4) (5) (6) I [dka- la-@254@122@2024@,Q@ Qk- la- 8¼122½@2024@Mhih@,uihih, -&fMoh& II] ORDER New Delhi, the 26th March, 2024 S.O. 1559 E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May , 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE Sl. No. Name of the Scheduled Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Remoglifloz in Etabonate, Vildagliptin & Metformin Hydrochloride tablets Composition: Remogliflozin Etabonate 100mg Vildagliptin 50mg Metformin Hydrochloride IP 500mg tablets 1 Tablet M/s Glenmark Pharmaceuticals Limited 8.76 2. Remogliflozin Etabonate, Vildagliptin & Metformin Hydrochloride tablets Composition: Remogliflozin Etabonate 100mg Vildagliptin 50 mg Metformin Hydrochloride IP 1000 mg tablets 1 Tablet M/s Glenmark Pharmaceuticals Limited 9.06 3. Ceftazidime and Avibactam powder for concentrate for solutio n for infusion Each vial contains: Ceftazidime (As Ceftazidime pentahydrate) IP 2gram Avibactam Sodium eq. to Avibactam 0.5gm 1Vial M/s BDR Pharmaceuticals Internation Pvt. Ltd. / M/s Natco Pharma Limited 1696.43 Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2 (1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDM S and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premis es where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form -I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per inst ant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commo dities Act, 1955. (g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) t hereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, s tand(s) superseded. [PN/254/122/2024/F /F. No. 8(122)/2024/D.P./NPPA -Div.-II] YUVIKA PANWAR, Assistant Director Uploaded by Dte. of Printing at Government of India Press, Ring R oad, Mayapuri, New Delhi -110064 and Published by th e Controller of Publications, Delhi -110054.